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Summary
Parkinson’s (PD) and Alzheimer’s disease (AD) are the two most common neurodegen-
erative diseases and of growing importance for the rapidly aging population of indus-
trialized countries. A common feature of both diseases is the progressive accumulation
of proteins in insoluble aggregates, which are considered to play a fundamental role in
the pathogeneses ultimately resulting in marked neuronal loss. The histopathological
hallmark features of PD are called Lewy bodies (LBs) and Lewy neurites (LNs), both
consisting predominantly of aggregated a-synuclein (aSyn), while neuropathological di-
agnosis of AD relies on the presence of neurofibrillary tangles and senile plaques com-
prised of hyperphosphorylated tau-protein or amyloid-b (Ab), respectively. However,
the implicated pathological mechanisms and pathways contributing to these diseases are
still not fully understood and numerous studies emphasize the need for early diagnosis
before major neuron-loss occurs. Cerebrospinal fluid (CSF) is in close contact with the
central nervous system and therefore a valuable source of biochemical markers reflecting
pathological changes in the brain and spinal cord. For AD, three core CSF biomarkers
(Ab, total-tau & phospho-tau) have been identified and extensively validated over the
last years, while established biochemical markers are virtually absent for the diagnosis
of PD.
The aim of the thesis was to investigate proteome alteration in the presence of diﬀerent
types of protein aggregates and ultimately to identify novel biochemical markers of
disease. Therefore, transgenic mouse models of a-synucleinopathy or b-amyloidosis,
the hallmark neuropathological aspects of PD or AD, were used. These mice express
mutated human genes initially identified in patients suﬀering from familial forms of PD
or AD.
The first set of experiments focused on the identification of proteins altered in the
CSF of these models. This was done in an unbiased mass spectrometry-based shotgun
approach, which led to the quantification of 636 and 665 CSF proteins in aged A30P-
aSyn and APPPS1 cohorts, respectively. Both datasets contained transgene-related
CSF protein changes that have already been associated with PD or AD, such as amy-
loid precursor protein (APP)-derived peptides, TREM2, ApoE or neurofilament light
(NfL), but also yielded novel insights in protein alterations, such as LAG-3, CART and
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lysosomal proteins. Next, both datasets generated from A30P-aSyn and APPPS1 CSF
were compared and revealed a marked overlap of proteins deregulated in both models.
The second part of the thesis focused on NfL, which plays a key role in axonal sta-
bilization and gained attention as biomarker of axonal injury in multiple neurological
disorders. A validated immunoassay was used for the quantification of NfL in CSF and
plasma of A30P-aSyn, APPPS1 and a third mouse line expressing an A53T mutation in
aSyn. Markedly elevated levels were found in CSF and plasma of the mice at the same
age as the respective brain lesions became apparent. This demonstrates that CSF and
blood NfL increases are not specific for aggregated aSyn or b-amyloid and emphasizes
its potential as marker of axonal damage upon neurodegeneration.
In conclusion, hundreds of proteins were quantified in the CSF of mouse models for
a-synucleinopathy and b-amyloidosis. The datasets at hand provide novel and unbiased
insights in pathological processes on molecular level and reveal common and distinct
features of the respective pathology. The high proportion of hits related to PD, AD
and other neurodegenerative diseases, as evaluated in human-based studies, substan-
tiates the confidence in the high quality of the datasets and the translational value
of the mouse models. Taken together, these findings provide a rich resource for the
identification of novel biomarkers and their value concerning diﬀerential diagnosis.
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1 Introduction
1.1 Aging and neurodegeneration
From a biological point of view, aging reflects the process in which a variety of stres-
sors are no longer adequately counteracted by the body’s protective functions (Whalley
et al., 2004). For the brain, aging also means damage from oxidative stress, mito-
chondrial dysfunction, inflammatory processes and accumulation of potentially injuri-
ous proteins. All of those can lead to irreversible changes, such as altered metabolic
pathways, destabilization of neuronal membranes and cell death (Hipkiss, 2006; Leuner
et al., 2007; Morgan et al., 2007; Tosato et al., 2007). Therefore it is not surprising
that age is a major risk factor for a variety of neurodegenerative diseases, ranging from
Alzheimer’s disease to Parkinson’s disease and amyotrophic lateral sclerosis.
According to a study from the United Nations Population Fund (UNFPA), 11% of the
world’s population is aged 60 and older. By the year 2050, the share is estimated to
reach 22% (UNFPA, 2012). This will inevitably lead to a boost of people suﬀering from
age-associated neurodegenerative diseases if no countermeasures are taken. Therefore
it is of utmost importance to investigate and understand the molecular and cellular
mechanisms causing dementia, so that patients can be identified in early stage of disease
and successful treatments can be established.
1.2 Parkinson’s disease
Parkinson’s is a progressive multi-system neurodegenerative disease, aﬀecting mostly
the elderly population. The disease was named after James Parkinson, who, in 1817,
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published “An Essay on the Shaking Palsy”, describing six individuals suﬀering from a
disease he called “paralysis agitans”. He described it as “Involuntary tremulous motion,
with lessened muscular power, in parts not in action and even when supported; with a
propensity to bend the trunk forwards, and to pass from a walking to a running pace:
the senses and intellects being uninjured ” (Parkinson, 1817). Nowadays we know that
“the senses and intellects” can be aﬀected and that besides mentioned motor symp-
toms, non-locomotor symptoms can become apparent. Those symptoms may include
cognitive, sensory and behavioral deterioration, culminating in dementia, depression,
visual hallucinations, anxiety and sleep disturbances (Sveinbjornsdottir, 2016).
The incidence and prevalence of PD are on the rise, in concurrence with the aging
population in industrialized countries (Pringsheim et al., 2014). PD is estimated to
aﬀect 0,3% of the general population, or 1% of people over the age of 60, making
it the second most-common neurodegenerative disease after Alzheimer’s (de Lau and
Breteler, 2006). The average age of onset is between 50 and 70 years, while prevalence
further increases with age, reaching 3,5% in 85-89 year old europeans (De Rijk et al.,
1997; de Lau and Breteler, 2006; Clarke and Moore, 2007). In 2015, approximately 6.2
million people were suﬀering from this incurable disease worldwide (Vos et al., 2016).
Idiopathic –or sporadic– PD is the most common form of parkinsonism, lacking an
identifiable external cause, such as a family history of the disorder. Sporadic PD is
aﬀected by numerous factors influencing age of onset and course of disease. Hereditary
PD, on the contrary, has dominant genetic causes and is therefore often also referred to
as familial form of PD (FPD) accounting for 5 - 10% of all PD cases (Thomas and Flint
Beal, 2007; Lesage and Brice, 2009). Over the last years, genetic analyses have identified
a set of mutations causing FPD, such as point-mutations, duplications and triplications
of the a-synuclein (SNCA) gene. In addition, mutations in the gene coding for leucine-
rich repeat kinase 2 (LRRK2), or loss-of-function mutations in Parkin, PINK1, DJ-1
and ATP13A2 can cause FPD (Lesage and Brice, 2009; Ferreira and Massano, 2017).
Neuropathology of Parkinson’s disease
Parkinson’s Disease is typically characterized by a pronounced loss of dopaminergic neu-
rons in the substantia nigra pars compacta (SNpc) and the development of distinctive
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eosinophilic, proteinaceous inclusion bodies, named Lewy bodies (LBs) and dystrophic
Lewy neurites (LNs) (Gibb and Lees, 1988; Fearnley and Lees, 1991). LBs are con-
sidered a pathologically characteristic feature of PD and other synucleinopathies, such
as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) (Goedert
et al., 2013). The composition of LBs, which were first described by Fritz Heinrich
Lewy in 1912, were later identified as a mix of filamentous aSyn, neurofilaments and
ubiquitin (Spillantini et al., 1997). Although neuronal loss is pronounced in the SNpc,
deposition of aSyn can also be observed in other parts of the central nervous system,
including the amygdala and cortical areas (Braak et al., 2003; Braak and Del Tredici,
2009). Spreading typically happens along interconnected neuronal pathways, starting
in the anterior olfactory nucleus and the dorsal motor nuclei of the vagal and glos-
sopharyngeal nerves in the brainstem, spreading through the medulla oblongata and
the amygdala, before reaching the SNpc. In later stages of disease, pathology spreads
to the temporal mesocortex and finally reaches the neocortex (Braak et al., 2003). The
loss of dopaminergic neurons in the SNpc leads to striatal dopamine deficiency, which
accounts for most sensory-motor symptoms (Pires et al., 2017). To date it is still not
completely clear which molecular pathways lead to this pathological picture, but both
environmental and genetic factors appear to play major roles in disease susceptibility
(Thomas and Flint Beal, 2007; Shulman et al., 2011).
Despite intensive research, a cure for PD remains to be found, while current treatment
aims at improving and delaying motor symptoms through pharmacologic agents, such
as levodopa and dopamine agonists (Pires et al., 2017). Considering the longstanding
presymptomatic phase required to reach the full extent of disease, the need for early
diagnosis and treatment aiming at initial pathological processes is substantial.
a-synuclein genetics in PD
As the main component of Lewy bodies, aSyn plays a pivotal role in PD. Mutations, du-
plications and triplications of the SNCA gene locus have been identified to cause rare
familial forms of PD (Lesage and Brice, 2009). While duplications and triplications
increase the amount of produced a-synuclein causing a dosage-dependent disease phe-
notype (Ikeuchi et al., 2008), point mutations are more complex, altering propensities
of aSyn to oligomerize and form inclusions (Lázaro et al., 2014). Six mutations falling
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into this category have been found over the last years: A30P, E46K, H50Q, G51D,
A53T & A53E, as depicted in figure 1 (Polymeropoulos et al., 1997; Krüger et al., 1998;
Zarranz et al., 2004; Lesage and Brice, 2009; Proukakis et al., 2013; Appel-Cresswell
et al., 2013; Pasanen et al., 2014).
Figure 1 – The structure of a-synuclein and mutations linked to familial Parkinson’s disease
The human a-synuclein protein consists of 140 amino acids and is encoded by the SNCA gene. Residues
1-60 form the amphipathic region, containing four 11-residue repeats, composed of hexameric KTKEGV
domains (red), which have structural alpha helix propensity. Residues 61-95 form the central region
which includes the hydrophobic non-amyloid-b component (NAC) region able to form b-sheet structures.
The highly acidic tail, spanning from AA 96 to 140 likely has auto-inhibitory functions, maintaining the
natively unfolded structure of aSyn. All mutations linked to familial PD are located in the N-terminal
region (marked in black), while phosphorylation sites (marked in blue) are situated towards the C-term
(modified from Breydo et al., 2012 and Lázaro et al., 2014).
1.3 Alzheimer’s disease
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease characterized by
advancing dementia and deficits in cognitive abilities. Patients typically present with a
progressive loss of episodic memory, diﬃculties in word finding, disorientation in time
and place, but individuals can also suﬀer from emotional changes, depression, anxiety,
apathy and delusions (Burns and Iliﬀe, 2009; Alzheimer’s Association, 2013). The dis-
ease was first identified by Alois Alzheimer in 1901, who followed the case of the 51-year
old Auguste Deter (Alzheimer, 1907). Suﬀering from severe dementia, she described her
condition as “I have lost myself, so to say” when she was asked to write her name. Af-
ter Auguste Deter died in 1906, Alzheimer examined her brain histologically and found
two types of microscopic lesions he referred to as “senile plaques” and “neurofibrillary
tangles” (Fig. 2, Illustrations 2-5). These lesions were later characterized as proteina-
ceous deposits and considered to be hallmark pathological features of AD, which still
remain a valid and definite diagnosis for AD (Glenner and Wong, 1984b; Goedert and
Spillantini, 2006; Scheltens et al., 2016).
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Figure 2 – Historic illustrations of plaques from the brain of Auguste Deter
Illustrations 2-5 show histologically stained plaques from the brain of Auguste Deter. Drawn and published
by Gaetano Perusini in 1909.
While initially considered a rather rare disease, AD became the most common form of
dementia due to an increasing life-expectancy over the last century. In 2015, 46.8 million
people were estimated to suﬀer from AD, which also aﬀects millions of relatives and
caregivers. The economic burden of dementia, whereof AD has the largest contribution,
is supposed to reach a trillion US dollars by 2018 (Prince et al., 2015). With age being
a major risk-factor, AD is therefore often seen as a disease of the elderly. However,
early onset forms of the disease exist in 4-5% of patients with an onset before 65 years
of age (Mendez, 2012).
Neuropathology of Alzheimer’s disease
Senile plaques and intracellular neurofibrillary tangles (NFTs), as initially described by
Alois Alzheimer, remained an obscure observation of unknown composition for many
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decades. In the 1960, technical advance in form of electron microscopy helped to shed
first light on the characteristics of both structures. NFTs appeared to have a paired
helical filamentous structure, whereas the core of senile plaques was composed of amy-
loid structures (Terry, 1963; Kidd, 1963; Wiśniewski et al., 1976). Years later, a 39-42
amino acid peptide named amyloid-b (Ab) was identified as the main component of
senile- or amyloid-plaques, whereas the microtubule associated protein tau (MAPT,
Tau) was identified as the primary constituent of the paired helical structures form-
ing NFTs (Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Goedert et al., 1988). Tau
was later found to be hyperphosphorylated in NFTs, while phosphorylation impairs its
binding to microtubules (Grundke-Iqbal et al., 1986b). It has been suggested that the
progressive trait of AD is due to increasing numbers of brain region-specific Ab aggre-
gates and NTFs (Braak and Braak, 1991; Thal et al., 2002; Jucker and Walker, 2013).
Both of these lesions follow a defined propagation pattern throughout the course of dis-
ease, which can be used for post-mortem staging (Braak and Braak, 1991, 1995), but
also sparked the idea of proteinaceous seeds with prion-like properties in AD and other
neurodegenerative diseases (reviewed in Jucker and Walker, 2013; Nussbaum et al., 2013
and Walker and Jucker, 2015).
APP processing, amyloid-b peptide and genetic causes
Ab peptide, the main constituent of amyloid plaques found in the brains of AD patients,
is an approximately 4.3 kDa fragment proteolytically cleaved from the amyloid precursor
protein (APP). APP is a single-pass trans-membrane protein that can have various
isoforms generated by alternative splicing: APP751 and APP770 are expressed in non-
neuronal tissues, while APP695 is abundantly produced and metabolized in neurons
(Masters et al., 1985; Kang et al., 1987; Tanaka et al., 1988; Lee et al., 2008). The
gene encoding for APP is located on chromosome 21, which also leads to a genetic
predisposition and high prevalence of AD in people with Down’s syndrome (Kang et al.,
1987; Robakis et al., 1987; Schupf and Sergievsky, 2002). Therefore it is not surprising
that the first isolation of Ab from brain tissue succeeded from brains of deceased trisomy
21 patients (Glenner and Wong, 1984a). The Ab peptide is derived from cerebral
APP695 through sequential secretase cleavage and consists of 36-43 amino acids (Sisodia,
1992; O’Brien and Wong, 2011; Hamley, 2012). Depending on the secretases mediating
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proteolytic cleavage, APP can either be processed in the “non-amyloidogenic” pathway
or the “amyloidogenic” pathway.
In the non-amyloidogenic pathway (see Fig. 3 A), an a-secretase (ADAM10) cleaves
APP within the sequence of Ab and thereby prevents the production of (pathogenic) Ab.
This results in the generation of extracellular soluble APPa (APPsa) and a membrane-
spanning c-terminal fragment (CTF-a) (Esch et al., 1990; Sisodia et al., 1990; Sisodia,
1992). Subsequent cleavage of CTF-a by g-secretase results in the release of a soluble
peptide, named P3 and the left-over APP intracellular domain (AICD).
The g-secretase, a multi-subunit protease complex, consists of four proteins: Nicas-
trin, APH-1 (anterior pharynx-defective 1), PEN-2 (presenilin enhancer 2) and PSEN1
(presenilin-1). Mutations in the PSEN1 subunit have been shown to increase Ab42 pro-
duction in transgenic mouse models (further elucidated in section 1.4; Duﬀ et al., 1996).
This is easily explained by the role of g-secretase in the amyloidogenic pathway (see
Fig. 3 B), where APP is sequentially cleaved by b-secretase (BACE1) and g-secretase,
resulting in the production of Ab. As the initial step of the amyloidogenic pathway,
APP is cleaved by BACE1 at a cleavage site in the extracellular domain, 99 amino acids
from the C-terminus (Vassar, 1999). This generates soluble APPsb which is released
from the cell and the hydrophobic membrane-spanning 99 amino acid c-terminal frag-
ment (CTF-b or C99) (Selkoe, 1991). CTF-b is then cleaved by g-secretase into AICD
and a Ab peptide (Vassar, 1999; Haass et al., 2012). Depending on the exact cleav-
age site of the g-secretase and progressive cleavage steps, various Ab peptides (ranging
from 37 to 43 amino acids) can be generated from the initially released Ab48 and Ab49
peptides (Takami et al., 2009). In healthy subjects, the 40 amino acid peptide of APP
(Ab40) is the most abundant Ab species, whereas the more hydrophobic and presumably
pathogenic Ab42 is less abundant with an Ab42:Ab40 ratio of approximately 1:9 (Vigo-
Pelfrey et al., 1993; Yan and Wang, 2006; De Strooper and Annaert, 2010; Pauwels
et al., 2012). Ab42, in comparison to Ab40, is more susceptible to aggregate and form
Ab fibrils that may further aggregate into oligomers and form amyloid-plaques (Jarrett
et al., 1993; Yan and Wang, 2006; Thinakaran and Koo, 2008; O’Brien and Wong, 2011).
This goes in line with the frequent observation of an increased Ab42:Ab40 ratio in the
brains of AD patients, where this shift leads to altered aggregation kinetics and an
enhanced toxicity of Ab (Pauwels et al., 2012). Whether Ab has a normal physiological
function is not well understood and knockout-studies in mice have demonstrated that
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neither APP nor Ab are necessary for physiological functions (Hiltunen et al., 2009).
Figure 3 – Sequential cleavage of APP occurs by two pathways
(A) Non-amyloidogenic processing of APP involves sequential cleavage by a-secretase and g-secretase.
Ab production is abolished by a-secretase cleavage in the Ab region (blue). Instead a truncated peptide
(p3) is released. (B) Amyloidogenic processing of APP involves b-secretase and g-secretase cleavage,
resulting in the release of Ab, which then tends to form oligomeric fibrils accumulating in plaques. Both
pathways produce soluble extracellular domains (sAPPa and sAPPb) and identical intracellular C-terminal
fragments (AICD) (figure adapted from Thinakaran and Koo, 2008).
In 1991, John Hardy and David Allsop formulated the amyloid cascade hypothesis,
trying to explain the underlying pathology inevitably leading to neuronal death and
the clinical phenotype known as Alzheimer’s disease. In short: Amyloid deposition is
a consequence of surplus Ab which is the result of Ab overproduction (e.g. trisomy 21)
and/or diminished clearance (e.g. ineﬀective breakdown of Ab). This is then followed
by abnormal phosphorylation of tau protein and the formation of NFTs, ultimately
resulting in neuroinflammation, neuronal death and the manifestation of disease (Hardy
and Allsop, 1991; Hardy and Higgins, 1992).
The amyloid cascade hypothesis is further supported by pathogenic mutations in APP
leading to familial forms of AD (FAD, Fig. 4). Such mutations are often autosomal
dominantly inhehenrited in specific families, where first signs of dementia usually oc-
cur rather early in life (http://www.alzforum.org/early-onset-familial-ad, last accessed
July 4th, 2017). In these families, three major genes have been identified that can
8
1 Introduction
cause FAD when mutated: APP (51 mutations, 121 families), Presenilin-1 (PSEN1, 219
mutations, 480 families) and Presenilin-2 (PSEN2, 16 mutations, 34 families) (http://-
www.molgen.ua.ac.be/ADmutations/ last accessed may 25th, 2017).
In APP, most pathogenic mutations cluster near the g-secretase cleavage site (Fig. 4),
except the “Swedish” and some other mutations that are located adjacent to the b-
secretase cleavage site (O’Brien and Wong, 2011; Haass et al., 2012). Mutations in
the presenilin gene generally have the same eﬀect as APP mutations and lead to an
increased production of Ab42 (De Strooper, 2007; Shen and Kelleher, 2007). However,
the substitution of alanine-to-threonine at codon 673 (A673T) confers protection against
development of AD by making APP a less favorable substrate for cleavage by BACE1,
therefore reducing production of Ab (Jonsson et al., 2012; Maloney et al., 2014).
In contrast to FAD, the causes of late-onset sporadic AD (SAD), accounting for more
than 95% of all AD cases, are largely unknown (Goedert and Spillantini, 2006). Nu-
merous studies have been conducted and led to the identification of several risk-factors,
such as age, diabetes, depression, hyptertension, traumatic brain injuries and genetic
disposition (Burns and Iliﬀe, 2009). The genetic component of SAD is mainly conferred
by mutations in TREM2 or variations in apolipoprotein E (APOE) alleles. Mutations in
TREM2 have been associated with a 3 to 5 fold increased risk to develop AD (Guerreiro
et al., 2013; Jonsson et al., 2013), whereas the APOE-E4 allele, present in 10%–20%
of various populations (Singh et al., 2006), triples the risk to develop AD when ex-
pressed heterozygously, while homozygous expression increases the risk by a factor of
15 (O’Brien and Wong, 2011).
Despite very distinct causes, the underlying pathology of familial AD, including amy-
loid deposition, the buildup of NFTs and neuroinflammation, is strikingly similar to
sporadic AD. Their similarity is further supporting the amyloid cascade hypothesis, as
Ab deposition is the primary event in sporadic AD (Shepherd et al., 2009).
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Figure 4 – Mutations in APP associated with familial Alzheimer’s disease
Various APP mutations are known to cause early-onset or familial forms of AD. Known mutations and
their respective amino-acid modification are indicated in the scheme. Mostly clustered in close proximity
of secretase cleavage sites, these mutations thereby influence APP processing. Said mutations can be
found both in- and outside the Ab sequence (highlighted in blue) and are usually named after the origin of
identified families. Mutations in the genes coding for Presenilin 1 and 2 (PSEN1, PSEN2) alter g-secretase
activity and therefore increase the production of the highly amyloidogenic Ab42 isoform (modified from
Van Dam and De Deyn, 2006).
1.4 From familial cases to mouse models of PD and
AD
Over the last years, transgenic mouse models have been used in various studies to gain
better understanding of the characteristics and underlying mechanisms of neurodegen-
erative disorders, including PD and AD. Such genetically altered mice may never reflect
the full extent of human pathology, but have proven to hold great translational value in
the search for biomarkers suitable for diagnosis in pre-clinical stages of disease (Antony
et al., 2011; Maia et al., 2015; Bacioglu et al., 2016).
For PD, the first identified mutations causing familial PD were located in the gene
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encoding aSyn (Polymeropoulos et al., 1997; Krüger et al., 1998), which gave rise to
the generation of numerous mouse-lines overexpressing aSyn under several promotors
and with various mutations (Fernagut and Chesselet, 2004), such as mice expressing
either A30P or A53T mutated human aSyn (Krüger et al., 1998; Polymeropoulos et al.,
1997). Yet it must be mentioned that mutated aSyn is only found in a small subset
of PD patients. However, a common feature of aSyn transgenic models and human
pathology is the advancing accumulation of aSyn in LBs, which is a hallmark feature
of PD and other synucleinopathies (Forno, 1996; Antony et al., 2011; Goedert et al.,
2013).
The first generated mouse line mimicking familial PD was the Thy1-hA30P-aSyn line,
carrying a A30P mutation in aSyn, expressed under a neuron-specific murine Thy-1
promoter (Krüger et al., 1998; Kahle et al., 2000). In homozygous mutants, as used
here, the level of mutated aSyn in the brain is two-fold over levels of endogenous murine
aSyn (Kahle et al., 2000). A Lewy-like deposition of aSyn inclusions can predominantly
be found in the substantia nigra and the spinal cord. Progressive motor impairments,
such as spastic hind-limb paralysis and hunchback posture usually occur between 16
and 20 months of age, which is delayed by approximately one year when the transgene
is expressed heterozygously (Neumann et al., 2002).
Another mouse line expressing a mutated human aSyn gene is the Thy1-hA53T-aSyn
model. The A53T aSyn mutation was initially described in families suﬀering from FPD
(Polymeropoulos et al., 1997; van der Putten et al., 2000). These mice show a very early
onset of symptoms usually between 2 to 6 months of age with a marked deterioration
of motor functions, even with heterozygous transgene expression. The features of the
induced a-synucleinopathy are strikingly similar to those observed in human brains with
Lewy pathology and neuronal degeneration with a particular vulnerability of motor
neurons and the brain stem (van der Putten et al., 2000).
Similar to the AD models, transgenic generation of mice mimicking the hallmark
pathologies of AD was also inspired by genetic profiling in families suﬀering from early-
onset FAD. Three main genes promoting early-onset FAD were identified. Besides mu-
tations in the genes coding for presenilin 1 & 2 (PSEN1, PSEN2) (Sherrington et al.,
1995; Levy-Lahad et al., 1995), numerous mutations were found in the APP gene (Van
Broeckhoven et al., 1990; Goate et al., 1991). As depicted in Figure 4, most pathogenic
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APP mutations happen to be next to b and g-secretase cleavage sites and have the
same eﬀect as mutations in presenilin 1 & 2, which alter APP processing and thereby
increase production of Ab42 (De Strooper, 2007; Shen and Kelleher, 2007).
The APPPS1 mouse line is co-expressing two mutated human genes: APP and Presenilin-
1. The APP harbors the “Swedish” mutation, where lysine and methionine at codon 670
and 671 are substituted with a asparagine and leucine (KM670/671NL). In the trans-
genic presenilin-1 gene, leucine is substituted with proline at codon 166. The model was
developed by Radde et al. in 2006 and is commonly used as models of b-amyloidosis,
as they show age-related deposition of Ab in the brain (Radde et al., 2006). The line
has also proven to be useful in biomarker research , despite the absence of neurofibril-
lary tangles and only modest overall neuron loss (Jucker, 2010; Maia et al., 2013, 2015;
Bacioglu et al., 2016).
Figure 5 – Mouse models of neurodegenerative diseases used for CSF proteome analysis
A30P-aSyn and A53T-aSyn are single-transgenic models, expressing the gene for human aSyn with
an alanine-to-proline substitution at codon 30, or an alanine-to-threonine substitution at position 53.
APPPS1 co-expresses the “Swedish” mutated gene for human APP and a mutated gene for Presenilin 1
with a leucine-to-proline substitution at codon 166.
1.5 Biomarkers of PD and AD
Chronic neurodegenerative disorders, such as AD and PD, typically have slow progres-
sion and partly overlapping symptomatology. Tissue sampling for direct visualization
is impossible in a clinical setting, urging methods for accurate – and, ideally, also
early – diagnosis, before widespread neuronal death occurs. Thus it is a major aim of
biomarker research to provide clinicians with biochemical or imaging tools suited for
timely diagnosis and tracking of disease progression (Olsson et al., 2011; Blennow et al.,
2016).
Over the last years, neuroimaging has proven to be useful for the diagnosis of AD
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and is routinely done with positron emission tomography (PET), a cost-intensive nu-
clear imaging technique showing in-vivo ligand binding and metabolic processes. The
imaging-agents used in AD PET scans typically aim at fibrillar Ab and aggregated tau
protein (Klunk et al., 2004; Mintun et al., 2006; Villemagne et al., 2015; Brier et al.,
2016). For the diagnosis of PD, such scans have proven challenging, albeit they can be
used to assess dopaminergic function in the basal ganglia and exclude other diseases
(Brooks, 2010; Loane and Politis, 2011).
Cerebrospinal fluid (CSF) is an ultrafiltrate of blood, produced in the ventricles and
around the blood vessels of the central nervous system (CNS). It circulates and en-
compasses brain and spinal cord, draining into blood with a turnover time of approxi-
mately 8 h in human (Hühmer et al., 2006). Due to its close contact with the central
nervous system, it is a valuable source for biochemical markers, reflecting pathologi-
cal changes in brain and spinal cord (Halbgebauer et al., 2016). For AD, three core
CSF biomarkers have been identified and extensively validated in various studies. These
core-biomarkers include total tau (T-tau), phosphorylated tau (P-tau) and Ab42, which
reflect key elements of AD pathophysiology (Hampel et al., 2004). Reduced CSF lev-
els of Ab42 are thought to be a result of amyloid deposition, where Ab42 binds and
thereby reduces its diﬀusion to the CSF (Strozyk et al., 2003). Increased amounts of
T-tau reflect cortical neuronal loss, while a reduced CSF P-tau levels coincide with
cortical tangle formation (Hesse et al., 2001; Buerger et al., 2006; Tapiola et al., 2009).
Those biomarkers have high diagnostic accuracy for AD, with sensitivity and specificity
reaching 85–90% (Blennow et al., 2010). In addition various other proteins have been
proposed as biomarkers for AD, such as TREM2 and neuron-specific enolase (NSE),
but did not reach sensitivity and specificity of the mentioned core biomarkers (Blennow
et al., 1994; Kleinberger et al., 2014; Schmidt et al., 2014; Suárez-Calvet et al., 2016).
To date there are no validated biochemical markers for PD and diagnosis is still reliant
on clinical criteria, when the disease is already advanced. For successful therapy, diag-
nosis needs to happen as early as possible. Biochemical markers are key for a timely
detection of PD and a prerequisite for the development of novel disease-modifying treat-
ment strategies, which are currently not available (Halbgebauer et al., 2016).
In analogy to the core biomarkers of AD, various studies have investigated the diagnos-
tic and prognostic value of a-synuclein, the major component of Lewy bodies and Lewy
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neurites (Tokuda et al., 2010; Wennström et al., 2013; Parnetti et al., 2014b). These
studies investigated the diﬀerent a-synuclein species – total, oligomeric and phosphory-
lated – , but data from these published studies are partly conflicting. CSF total aSyn
is usually reported as decreased, while oligomeric aSyn is often found to be increased
in PD patients (Tokuda et al., 2010; Wennström et al., 2013; Parnetti et al., 2014b,a;
Blennow et al., 2016). However, the prognostic value of CSF aSyn is questionable since
no correlation has been found between total or oligomeric CSF aSyn and disease pro-
gression (Parnetti et al., 2011; Compta et al., 2014). Other CSF biomarkers, mainly in
the context of oxidative stress, neuroinflammatory processes and neuronal injury, have
also been considered by the field. Amongst the particularly promising candidates are:
DJ-1, neurofilament light (NfL), synaptic proteins and lysosomal enzymes, due to their
importance in aSyn degradation (Webb et al., 2003; Lee et al., 2004; Magdalinou et al.,
2014; Parnetti et al., 2014a; Blennow et al., 2016).
1.6 The proteome
The term “proteome” describes the entire set of proteins expressed in an organism,
organ, cell, tissue or bodily fluid at a given time and condition. The science of global
protein composition and modifications in complex biological samples is usually referred
to as “proteomics”. Protein abundance, protein-protein interactions and the localization
of proteins are of particular interest when it comes to understanding molecular processes
and mechanisms in disease and models of disease.
Mass spectrometry in proteomics and label-free quantification
Mass spectrometry-based approaches represent the ideal tool to address the technically
challenging tasks of proteomic research in a fast, antibody-independent and unbiased
way. These approaches can roughly be split into bottom-up (shotgun) and top-down
strategies. While top-down proteomics typically aim at fragmentation and measure-
ment of isolated and undigested proteins to identify and quantify unique proteoforms
through the analysis of intact proteins (Durbin et al., 2016), bottom-up approaches
involve proteolytic digestion and can be used for analysis of complex mixtures from
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crude protein extracts (Aebersold and Mann, 2003). After initial protein extraction
and digestion, bottom-up experiments require separation of peptides by liquid chro-
matography and measurement by mass spectrometry. Mass spectrometers are capable
of detecting the mass-to-charge ratio (m/z) of charged molecules with high precision
and accuracy, which can later be used to calculate the mass of a respective molecule.
An established apparatus often used in proteomic research is the combination of a nano-
LC system, an ion source and an Orbitrap mass spectrometer. In this array, peptides
are gradually eluted from the LC column and ionized subsequently by electrospray ion-
ization (ESI). The charged peptides are then transferred through the ion optics, the
quadrupole mass filter, gathered in the c-trap and injected into the orbitrap mass-
analyzer (Fig. 6). The Orbitrap mass-analyzer contains a spindle-shaped electrode,
forcing peptides to oscillate in their characteristic axial oscillation frequency which is
proportional to the square root of m/z (w=
q
k
m/z ). This allows very precise measure-
ment of peptides m/z with a deviation of ± 0.001 Da (Makarov, 2000). In the so-called
MS or MS1 mode, the signal intensity allows to quantify the proportion of peptides
in the sample. MS signal intensity correlates with concentration and can therefore be
used for quantification (Bantscheﬀ et al., 2007). To determine the amino acid sequence
and thus identify the peptides and proteins, charged peptides of a specific m/z are
sequentially collected in the c-trap, forwarded into the HCD cell and fragmented by
collision with an inert gas (CID, collision induced dissociation). Resulting fragments
are then analyzed in the orbitrap mass-analyzer to gain spectra from fragments of dif-
ferent size. Discrepancies in the fragment masses can then be matched to the specific
molecular masses of amino acids. This procedure, and spectra generated from it, are
usually referred to as MS/MS or MS2. In the last step, acquired MS1 and MS2 spectra
are matched to peptide and protein databases, resulting in a list of proteins identified
by their respective peptides (Michalski et al., 2012).
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Figure 6 – Schematic design of a Q-Exactive mass spectrometer
The Q-Exactive is a state-of-the-art MS device, capable of detecting the mass-to-charge ratio of ionized
peptides in the Orbitrap operated at MS1 and MS2 mode. This allows the quantification and identification
of peptides which can later be assigned to proteins. Figure adapted from www.thermofischer.com
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2.1 Mice
A variety of transgenic mouse models were used to analyze diﬀerences in CSF proteome
composition and for validation of the measurements (see also Fig. 5):
[A30P]aSYN (Thy1-hA30P-aS) mice (Kahle et al., 2000; Neumann et al., 2002), over-
expressing human A30P-mutated a-synuclein under the control of a murine Thy1-
promoter, were kindly provided by Prof. P. J. Kahle (University of Tübingen). In
this model of a-synucleinopathies, a severe and lethal motor phenotype rapidly devel-
ops in aged homozygous mice (18±2 months), but not in heterozygous animals of the
same age.
[A53T]aSYN (Thy1-hA53T-aS) mice (van der Putten et al., 2000) also express human
a-synuclein under the same murine Thy1-promoter, but with an A53T mutation in
a-synuclein. This model was kindly provided by Dr. D.R. Shimshek (Novartis). Het-
erozygous mice develop severe and fatal motor-symptoms very rapidly at young age
(8±1 months).
The aSyn-transgenic mice were routinely monitored, occurrence and severity of motor
symptoms was assessed based on a score sheet. In addition, the body weight was tracked
constantly as clinical parameter to define humane endpoints.
As a model for beta-amyloidosis, we used APPPS1 (Thy1-hKM670/671NL-APP; Thy1-
hL166P-PS1) mice (Radde et al., 2006), which co-express KM670/671NL mutated hu-
man APP and L166P mutated human PS1 under the control of the same neuron-specific
murine Thy1 promoter element used in both a-Syn-transgenic models.
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For validation of MS results, Lag3 knockout (KO) mice (B6.129S2-Lag3tm1Doi/J)
(Miyazaki et al., 1996), were purchased from Jackson Laboratories (Bar Harbor, ME,
USA), kept and bred in the animal facility of the Hertie institute prior to sample collec-
tion. Those mice are deprived of Lag3 expression by a null-mutation of the endogenous
Lag3 gene.
All mice were maintained on a C57BL/6 background and kept under specific pathogen-
free conditions in a 12 h light/dark cycle. The experimental procedures were carried out
in accordance with the veterinary oﬃce regulations of Baden-Württemberg (Germany)
and approved by the local Animal Care and Use Committees.
2.2 CSF and blood sampling from mice
CSF and blood were collected from anesthetized transgenic A30P-aSyn, APPPS1, Lag3-
KO mice and age-matched non-tg wildtype (WT) littermates. The CSF collection was
done according to standards set by the Alzheimer’s Association external quality control
program for human CSF biomarkers (Mattsson et al., 2011). In order to minimize
eﬀects by circadian proteome fluctuations, CSF sampling was always performed between
1 and 7 PM. Mice were deeply anesthetized with a mixture of ketamine (100 mg/kg
bodyweight) and xylazine (10 mg/kg bodyweight) and placed on a heat pad to ensure
a stable body temperature during CSF sampling.
After incision of the overlying skin and retraction of posterior neck muscles, the Dura
mater, covering the Cisterna magna, was carefully cleaned with cotton swabs soaked
with PBS or ethanol. In case of bleedings in the surrounding tissues, hemostyptic gauze
(Tabotamp, Ethicon) was used to keep the Dura mater spared from blood contamination
(Fig. 7). Next, the Dura mater was air-dried and subsequently lanced with a 30G
needle (BD Biosciences). CSF was collected with a 20 µL gel loader tip (Eppendorf,
shortened), transferred into polypropylene tubes (Eppendorf) and placed on ice. CSF
was always collected immediately after puncturing of the Dura and up to three minutes
later. Typically, a total volume of 15-25 µL was collected per mouse. The samples
were then centrifuged for 10 min at 2000 RCF, assessed macroscopically for blood
contamination, aliquoted and stored at -80°C until further usage. Samples aﬀected by
blood contamination were discarded.
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Figure 7 – CSF preparation in mice
After incision of the skin, retraction of neck muscles and cleaning, the Dura mater can be punctured and
CSF can be collected. (A) Dorsal view on a mouse Cisterna magna shortly before CSF collection and
(B) sagittal illustration of the CSF collection procedure, note the shallow depth of tip-insertion to avoid
tissue and vessel ruptures.
Next, blood was collected from the right cardiac chamber with a syringe containing
EDTA to prevent coagulation. To obtain serum, samples were centrifuged at 2000 RCF
for 10 min, aliquoted and stored at -80°C until use.
Sampling of A30P-aSyn mice, and respective control animals, was done in young (3 months
of age), presymptomatic/medium aged (11 months) and symptomatic/aged animals
(19±1 months) of both sexes, while CSF and blood of APPPS1 mice were collected
from young (3 months of age) and aged (18 months) males and age-matched litter-
mates.
2.3 Brain sampling from mice
After CSF and blood sampling, heart and vessels were perfused to flush remaining blood
from brain- and other arteries. For this purpose, the left cardiac chamber was punctured
with a needle and slowly flushed with 12 mL of sterile PBS (4°C, Lonza, Switzerland).
The brain was then removed, split into hemispheres and subsequently frozen in liquid
nitrogen, or fixed by incubation in PFA (4%, in PBS, 48h) and cryoprotected in sucrose
(30% in PBS).
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2.4 CSF proteome analysis
Figure 8 –Workflow and methods utilized for the analysis of individual A30P-aSyn, APPPS1
and WT CSF proteomes
CSF was collected from the Cisterna magna of anesthetized mice; proteins were digested with Lys-C
and Trypsin, before wash and desalting steps on C18 STAGE-Tips. Resulting peptides were eluted from
the STAGE-Tip before subsequent loading and elution from a nano-LC system. Peptides were ionized by
electrospray-ionization before injection into an Q-Exactive Orbitrap mass spectrometer. Resulting spectra
were loaded in MaxQuant and searched against a Uniprot database.
Sample processing
Denaturation Per mouse, 5 µL of CSF were diluted in 45 µL of denaturation buﬀer
(6 M urea, 2 Thiourea in 10 mM HEPES pH 8.0). 5 µL of a 10 mM Dithiothreitol
(DTT) solution was added and the sample incubated for 30 min to reduce disulfide
bonds on proteins. Cysteines were alkylated by adding 5 µL of 55 mM Iodoacetamide
(IAA) solution and incubation for 20 min in the dark. Excess of IAA was removed by
addition of 5 µL 10 mM DTT and 30 min of incubation. All incubation steps were
conducted at room temperature.
Enzymatic digestion The samples were pre-digested by the endopeptidase LysC and
incubated for 3 h, prior to dilution in 100 µL of 50 mM ammonium bi-carbonate (ABC)
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and digestion with Trypsin over night. After digestion, samples were desalted, washed
using in-house prepared C18 (3M, USA) STAGE-Tips (Rappsilber et al., 2003), dried
by vacuum centrifugation and re-dissolved in 20 µL of 0.1% formic acid.
LC-MS/MS analysis
For the sake of reducing sample complexity, 8 µL of previously digested and re-dissolved
CSF samples were separated in a nano-LC system coupled online via a nanospray flex
ion source or via an Easy-spray system (all from Proxeon - Thermo Scientific, US) to a
Q-Exactive mass spectrometer (Thermo Scientific, US). The scan resolution in full scan
mode was set to 70’000 (m/z range: 300-1400). The top 10 precursor ions (determined
by intensity, exceeding an intensity of 2x104), were further fragmented by collision
induced dissociation with nitrogen gas. Spectra of resulting fragments were acquired at
a resolution of 17’500. Precursor ions chosen for dissociation were included in a dynamic
exclusion list for 60 seconds and blocked from repeated peptide fragmentation.
Data analysis & statistics
The spectra generated by MS were analyzed in the MaxQuant software-suite version
1.5.3.12 (Cox et al., 2014). This program searches and matches the generated spec-
tra to a reviewed canonical FASTA database containing 16725 entries for mouse (Mus
musculus) proteins; downloaded from UniProt (downloaded: August 26th 2015). The
database was furthermore supplemented with a list of typical contaminants and the
transgenic proteins of the mouse models used. Trypsin was defined as protease to as-
sure correct in silico digestion of the proteins. A maximum of two missed cleavages were
allowed for the database search. Peptide masses were pre-calibrated within a window of
20 ppm, by activating “first-search”, leading to a more precise main search. Main search
mass tolerance was set to 4.5 ppm for peptides and peptide fragment mass tolerance
was set to 20 ppm. Acetylation of the protein N-term and oxidation of methionine
were chosen as variable modifications. The false-discovery rate (FDR) for protein and
peptide identification was set to  1%, using a target-decoy approach searching an
integrated forward/reverse database. For label-free quantification (LFQ) of proteins,
ratio counts of at least two unique peptides were required and quantification was done
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solely on unique peptides. For the APPPS1 dataset, samples were measured in two
separate LC-MS/MS sessions and batches were normalized in order to combine them.
Therefore we normalized LFQ intensities of each protein group and sample to the re-
spective mean LFQ intensities of aged (18 months) control animals. Normalization of
the LFQ algorithm was disabled to account for age dependent CSF protein concentra-
tion diﬀerences, thus preventing global eﬀects on quantification. The Perseus software
package (Cox and Mann, 2012; Tyanova et al., 2016) version 1.5.2.6 was used to import
and further analyze the data from MaxQuant. Correlation of technical or biological
replicates were used to estimate the quality of each single measurement and helped to
identify LS-MS/MS runs with technical issues, which were manually reviewed for proper
LC-elution and excluded from further analysis otherwise. LFQ intensities of technical
replicated were averaged, when possible, otherwise the LFQ intensity of a single tech-
nical replicate was used for the following steps. Potential contaminants, reverse hits
or only hits only identified by site were filtered from the dataset and excluded from
analysis. Next, LFQ intensities were log2 transformed and two-sided student’s t-tests
were carried out for each protein group to evaluate statistically significant regulated
proteins. This was done for control mice and transgenic mice of the same age group. A
p-value of 5% was set as initial significance threshold, while a permutation-based FDR
estimation (250 randomizations, S0 = 0.1) was performed in addition to compensate for
false positive hits generated by the large number of t-tests. For more reliable results, a
minimum of three valid LFQ intensities per protein and experimental group was reuired
for statistical tests.
Ontological enrichment analysis
In order to identify subsets of altered proteins in our filtered datasets, various enrich-
ment analyses were conducted. Ingenuity Pathway Analysis IPA® (Quiagen, Germany)
and DAVID 6.8 (http://david.ncifcrf.gov) (Huang et al., 2009a,b) provided deep insight
into the datasets changed protein composition. For IPA, a p-value < 5% and a log2
fold-change > ± 0.5 were set as thresholds. For DAVID analysis, significantly enriched
proteins were searched for Kyoto Encyclopedia of Genes and Genomes (KEGG) and
Gene Ontology (GO) annotations, while all reliably quantified proteins (quantified in
  3 animals in each transgenic and WT groups) were set as background. The following
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GO databases were searched: “CC_DIRECT”, “BP_DIRECT” and “MF_DIRECT”.
Thresholds for functional annotation were set to a minimum count of 2 and an EASE
score of 0.1 (a modified Fisher Exact p-value; smaller , more enriched).
2.5 SDS-PAGE and immunoblotting
Samples were analyzed on 4-12% NuPAGE Bis-Tris mini gels, using NuPAGE LDS
sample buﬀer (Invitrogen, USA). For immunoblotting, samples were transferred onto
nitrocellulose membranes, followed by blocking in 3% BSA and 5% skim milk, then
probed over night in monoclonal mouse antibody raised against murine LAG3 (4-10-C9
MABF954; Merck Millipore). Proteins were visualized using horseradish peroxidase-
conjugated secondary antibodies and the SuperSignal West Dura chemiluminescence
system (Thermo) exposed on Amersham Hyperfilm ECL (GE Life Sciences). Quantifi-
cation of bands was done in ImageJ software v1.50i (Schneider et al., 2012). Statistical
analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA,
USA). Groups were compared using Bonferroni’s post hoc test. Statistical significance
level was set as follows: * if p < 0.05, ** if p < 0.01, *** if p < 0.001.
2.6 Electrochemiluminescence immunoassay for NfL
NfL levels were measured in duplicates using an electrochemiluminescence (ECL) im-
munoassay with some modifications (capture monoclonal antibody: 47:3; biotinylated
detector monoclonal antibody: 2:1, Uman-Diagnostics AB, Sweden) (Gaiottino et al.,
2013). Murine CSF (5 µL) and plasma were pre-diluted (1:14 & 1:2) in sample buﬀer
(TBS containing 1% BSA, 0.1% Tween 20). For brain NfL measurements, fresh frozen
brain hemispheres were homogenized to 10% (w/v) in homogenization buﬀer (50 mM
Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, Pierce protease and phosphatase inhibitor
cocktail) and subsequently centrifuged (25’000 x g; 4°C, 1 hr). Supernatant was diluted
1:1’000 in sample buﬀer. NfL specificity of the assay was confirmed with samples from
NfL-deficient mice. CSF and blood samples were measured on the same plate. Sam-
ples with coeﬃcients of variation (CVs) > 20% between duplicates were re-analyzed.
All measurements were performed blinded. Statistical analysis was done in GraphPad
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Prism 6.0 (GraphPad Software, San Diego, CA, USA). Diﬀerences between age groups
or transgenics and WT of the same age group were compared using Bonferroni’s post
hoc test for multiple comparisons. Statistical significance level was set as follows: * if
p < 0.05, ** if p < 0.01, *** if p < 0.001.
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3.1 Shotgun proteomics in the search for CSF
biomarkers
Mouse models of disease, such as a-synucleinopathies and b-amyloidosis, provide the
chance to discover protein alterations solely caused by underlying core pathologies
and associated processes. These mice hold great translational value for the search of
biomarkers, not only because they are spared from concomitant diseases, but can also
be kept in controlled environments, unaﬀected from medication and other treatment.
These advantages result in a clear reflection of disease associated events and facilitate
identification of common and pathology-specific protein alterations.
3.2 CSF proteome complexity
CSF proteome is a complex mixture of proteins
The number of spectra, identified peptides and protein groups allows an initial estima-
tion of the respective dataset quality. This was done separately for both LC-MS/MS
experiments:
A30P-aSyn In total, the label free LC-ESI-MS/MS shotgun analysis yielded over 2.6
million MS/MS spectra from 42 mouse CSF samples. Those spectra led to the detec-
tion of 11609 peptide sequences originating from 1333 protein groups. After filtering
out potential contaminants, reverse hits and hits only assigned by site, 1261 protein
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groups were identified and quantified in the CSF of 3, 11 and 18 months old A30P-
aSyn transgenic and age-matched control mice (Tab. 1). Those 1261 proteins were
used for further analysis. This corresponds to an average of 598 ± 87 (mean ± SD)
protein groups per mouse, quantified in just 2 µL of CSF.
APPPS1 Close to four million MS/MS spectra were generated from APPPS1 and
corresponding control samples, the 31 CSF samples were measured in duplicates, which
resulted in 11591 peptides that were assigned to 1256 protein groups (Tab. 1). After
filtering, 1168 protein groups were left for analysis. On average 568 ± 106 (mean ±
SD) protein groups were quantified per mouse.
Table 1 – CSF proteomes by numbers
A30P aSyn APPPS1
MS/MS Spectra submitted 2 604 601 3 964 242
MS/MS Spectra identified (% of submitted) 166 267 (6,4%) 223 322 (5,6%)
Peptides identified 11609 11591
Protein Groups identified 1333 1256
Protein Groups identified without C,R,S 1261 1168
Proteins quant. in   3 mice in TG and WT at 18 mo 636 665
at 11 mo 526 -
at 3 mo 545 580
CSF proteome mainly consists of secreted and
membrane-associated proteins
We sought to obtain a general overview of the proteome composition represented in the
CSF of mice analyzed. With the CSF being in close proximity to the brain and blood
vessels, cell degeneration or blood contamination may obscure biomarker changes and
aﬀect further analysis. Therefore, we used the subcellular location, assigned by UniProt
SL-terms, as a proxy to untangle the origin of proteins detected in the CSF.
Consistently in both models and the respective controls, “Secreted”, “Membrane” and
“Cytoplasm” were the most frequently assigned SL-terms, with “Secreted” being repre-
sented in 31 - 37% of all proteins. Devoid of any quantitative data, the actual proportion
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Table 2 – Representation of UniProt terms “subcellular location”
A30P aSyn dataset APPPS1 dataset
A30P aSyn [%] WT [%] APPPS1 [%] WT [%]
Cytoplasm 30,4 32,0 28,7 29,0
Membrane 31,5 31,0 29,7 29,9
Nucleus 13,0 13,5 11,1 12,8
Mitochondrion 3,9 3,7 2,8 3,8
Secreted 32,6 31,4 36,8 35,2
Unknown 16,0 17,5 15,6 16,5
of secreted protein in CSF is assumed to be higher. The protein annotation “Mitochon-
drium” makes up the smallest share (2,8 - 3,9%) of all SL-terms considered (Tab. 2).
A low fraction of mitochondrion and nucleus aﬃliated proteins demonstrate minor, if
any, eﬀects of tissue, cell and blood contamination. Since proteins often have complex
functions and can be found in multiple compartments, SL terms are not exclusive and
values add up to more than 100%.
3.3 CSF proteome of aSyn transgenic mice
(A30P-aSyn)
After surveying overall CSF proteome composition, we looked for proteins distinctly
shifted from their corresponding level in non-transgenic age-matched controls. As a
prerequisite for statistical testing, respective protein groups had to be quantified in at
least three biological replicates in A30P-aSyn and control animals.
In young animals of 3 months, CSF proteome composition of transgenic animals is quite
akin to controls, whereas peroxiredoxin-2 is closest to reach significance. While ongoing
formation of a-synuclein lesions in presymptomatic mice has little influence on most
protein levels, CSF concentration of cocaine- and amphetamine-regulated transcript
protein (CART) -or derived peptides- is 2-fold higher than in age-matched controls
(p = 0,0001, Fig. 10 B ). In 18 month old A30P-aSyn mice however, levels were back
to baseline and control levels.
In symptomatic animals, at approximately 18 months of age, a total of 220 protein
27
3 Results
groups passed the stringent significance cutoﬀ (Fig. 9). Amongst the most altered
CSF proteins were complement C4, serotransferrin, triggering receptor expressed on
myeloid cells 2 (TREM2), gamma-enolase (ENO2), chitinase-3-like protein 1 (YKL-
40), lymphocyte activation gene 3 protein (LAG3), clusterin (Clu), granulin (Grn),
apolipoprotein E (ApoE) and neurofilament medium polypeptide (NfM) (Figs. 9, 10
C-G & Tab. 3). NfM is the most significantly altered protein with levels approximately
1500-fold those found in control animals. All of those proteins had elevated levels in
A30P-aSyn, while only six out of the 220 proteins had reduced levels compared to
controls (Fig. 9 & Tab. 4). Both tables 3 & 4 are ranked according to p-value of
A30P-aSyn versus controls at 18 months.
Another noteworthy trend is a general increase in various cathepsins and components
of the complement system (Fig. 16). Proteins not detected in any of the groups to be
compared, likely due to restrictions with the lower detection limit, cannot be integrated
in this analysis. This concerns a small subset of proteins including NfL, which had
considerably high LFQ-intensities in symptomatic A30P-aSyn, but was not quantified
in non-transgenic littermates (Fig. 10 H-L).
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Figure 9 – CSF proteome changes in A30P-aSyn compared to age-matched controls at 18,
11 and 3 months of age
The figure illustrates both, fold change diﬀerence of A30P-aSyn to WT and the p-value of pairwise
comparisons for each protein. Fold change diﬀerence is depicted on a log 2, p-value on a negative log 10
scale. Each dot represents a protein quantified in at least three A30P-aSyn and three control replicates
per group. The cutoﬀ for significance is indicated by a red curve, depicting the significance cutoﬀ of
permutation based FDR correction. Most diﬀerentially expressed proteins are labeled with their respective
gene name. Comparisons of transgenic versus control mice are based on 5 to 10 animals for each age group.
Proteins below detection limit and proteins not quantified in at least three biological replicates of both
groups compared, can not be considered in this figure.
We then chose a subset of proteins from the dataset and examined them in more detail,
including fluctuations across diﬀerent age groups (Fig. 10). As a proof of concept, we
quantified levels of aSyn-derived peptides and detected it almost exclusively in trans-
genic mice, with a marked 18 to 26-fold increase in symptomatic animals. Due to
high similarity of endogenous murine and human transgenic a-Syn (94% AA sequence
homology), the analysis did not diﬀerentiate between transgenic and endogenous a-Syn.
While TREM2 was not detected in young A30P-aSyn mice and is only slightly above
control levels at 11 months, it is considerably elevated at 18 months, exceeding WT-
levels by a factor of 12 (Fig. 10 C). A consistent and almost 4-fold increase of TREM2
is also detectable during “normal” aging in control animals. Levels of serpin A3N dou-
bled during normal aging, while its amount in 18 mo aSyn-transgenic mice was 32-times
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higher than in 3 month old A30P-aSyn and 20-times more than in 18 mo controls. Quan-
tification of LAG3 revealed quadrupling concentrations in control CSF during normal
aging and a 12-fold increase during aging in A30P-aSyn, resulting in an approximately
3.5 fold diﬀerence in the oldest age group (Fig. 10 E). In contrast to the previously
described proteins, aging has hardly any eﬀect on granulins, albeit granulin builds up
considerably in CSF from symptomatic aSyn mice. In general, variance in CSF NfM
amounts is quite prominent in young and intermediate age, but surprisingly consistent
at 18 months, while the average levels are increased by a factor of approximately 1500
in transgenic animals. For NfL, LFQ intensities are missing in all groups, expect for
symptomatic A30P-aSyn. Albeit this prevents any relative quantification, high LFQ in-
tensities indicate large amounts of NfL. As another member of the neurofilament group,
a-internexin shows a similar LFQ intensity-pattern, namely high LFQ intensities in aged
aSyn transgenic animals. In the other age groups identification and quantification of
peptides, allegedly originating from a-internexin, are exclusively based on “match be-
tween runs”, a computational algorithm increasing the number of quantifiable peptides.
Unfortunately, the algorithm can result in incorrect identification and quantification.
The same is true for depicted intensities of syntaxin-B1 in the 11-month groups. Fur-
thermore, tau and the synaptic proteins syntaxin and SNAP-25 were elevated in CSF
of symptomatic A30P-aSyn (Fig. 10 J-L).
Next, to pinpoint enriched subsets of altered proteins, we performed enrichment anal-
ysis searching Gene Ontology (GO) databases and KEGG annotations. Therefore 220
significantly altered proteins were submitted to DAVID, of which 198 were included in
the analysis. The results are shown in table 5 (described in 2.4 & 3.3). “Extracellular
region” was the most commonly found GO-CC (GO Cellular Component) term, associ-
ated with 125 out of 198 proteins included in the analysis. “Innate immune response”,
“inflammatory response” and “proteolysis”, amongst others, were found to be enriched
biological processes (GO-BP), while “Lysosome” was the most altered pathway accord-
ing to KEGG annotations, reflecting markedly increased levels of 16 lysosomal proteins
in the CSF of symptomatic A30P-aSyn mice.
We furthermore analyzed the whole dataset by IPA. It found “Autophagy”, “Atheroscle-
rosis Signaling” and an increased “LXR/RXR Activation” to be the top three dereg-
ulated pathways in symptomatic A30P-aSyn mice, amongst “Acute Phase Response
Signaling”, “Complement System” and others (Fig. 11 on top). In CSF from presymp-
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Figure 10 – Selected proteins in CSF of A30P-aSyn
Proteins quantified in CSF from A30P-aSyn mice and controls at 3, 11 and 18 months of age demonstrate
varying protein levels during aging in transgenics and controls. (A) Due to high homology of murine and
human transgenic aSyn distinction was not possible. (B) CART exhibits a distinct peak in A30P-aSyn
mice at 11 months, while TREM2, Serpin A3N, LAG3, Granulin and NfM have their highest levels in
symptomatic mice (C-G). (H-L) NfL, Tau, SNAP-25, Syntaxin-B1 and a-Internexin were exclusively or
predominantly quantified in symptomatic A30P-aSyn, with levels below detection limits or unreliable
quantification by spectral matching in the other groups. LFQ intensities are log2 transformed, n = 5-10
mice/group, Means ± SD are shown.
tomatic mice, only three pathways had a p-value slightly smaller than 5%, while a
surprisingly high number of pathways were altered in young mice at 3 months of age
(Fig. 11 mid and lower part). A small set of proteins (Apo-A1, Apo-A2, Apo-A4,
Apo-E, RBP4, Serpin A1) were represented in most of the pathways listed, highlighting
to these unexpected pathways.
31
3 Results
3.4 CSF proteome of APP transgenic mice
(APPPS1)
In analogy to the previously described CSF proteome analysis of A30P-aSyn mice,
we searched the CSF of APPPS1 mice for markers of cerebral protein deposition and
downstream pathological events. As mentioned earlier, a requirement for the analysis
was protein quantification in at least three mice per group to be compared.
As shown in figure 12 (right panel), statistical testing found no markedly altered proteins
in young animals. In aged mice however, eight proteins diﬀered significantly in APPPS1
and WT mice and passed the strict FDR-corrected significance cutoﬀ (Fig. 12, left
panel). All of those eight proteins, including NF-M, TREM2 and LAG3, had increased
CSF levels in transgenic mice. A list of the 25 most altered protein groups, including
the eight significant hits, is given in table 6 (significant hits are highlighted in italics).
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Figure 12 – CSF proteome changes in APPPS1 compared to age-matched controls at 18 and
3 months of age
Each dot represents a single protein quantified in APPPS1 and control animals. Log2-transformed fold
diﬀerence of mean APPPS1 to WT is plotted to the negative log 10 p-value of the pairwise comparison.
Significance cutoﬀ (red line) is based on permutation based FDR corrected t-tests and factors in p-value
and fold change. Most diﬀerentially expressed proteins were labeled with the respective gene name.
Comparisons of transgenic versus control mice are based on 7 to 8 males per age group. Proteins below
detection limit or not quantified in at least three biological replicates of both groups are not displayed in
this graph.
As expected, we detected transgenic human APP harboring the “Swedish” mutation in
APPPS1 mice exclusively (Fig. 13 A), while presenilin-1 was not quantified in any of
the samples. We also observed stable levels of murine APP independent of age and
transgene (Fig. 13 B). Notably, TREM2, serpin A3N, LAG3, granulin and NfM (Fig.
13 C-G) show the same, but less pronounced profile described in A30P-aSyn mice. All
of said proteins have substantially increased concentrations in aged APPPS1 mice, with
NfM showing the strongest eﬀect with a more than 10-fold increase. Lysozyme C-2 has
the smallest p-value of all proteins quantified in aged APPPS1 and WT mice, increased
by a factor of 3.2 (Fig. 13 H).
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Figure 13 – Selected proteins in CSF of APPPS1
Proteins quantified in CSF of APPPS1 mice and controls at 3 and 18 months of age show increased
protein concentrations in aged APPPS1, age-dependent increase is often also apparent in controls. (A,B)
As expected, transgenic human APP with Swedish mutation was exclusively found in APPPS1 mice, while
endogenous murine APP is stably found independent of age and transgene. (C-H) TREM2, Serpin A3N,
LAG3, NfM and Lysozyme C2 levels were considerably elevated in APPPS1 at 18 months of age, while
Granulin was quantified in insuﬃcient numbers to allow definitive conclusions. LFQ intensities are log2
transformed and normalized separately for each of both batches (see 2.4), n = 7-8 mice/group, Means ±
SD are shown.
Similar to the other dataset, eight significant hits were submitted to the DAVID func-
tional annotation tool, searching previously mentioned GO and KEGG databases. Un-
fortunately, four out of the eight proteins were not represented in any of the enriched
annotation clusters, which left cathepsins B, C, Z and TREM2 for the analysis. This led
to the identification of cathepsin- and lysosome-associated GO-Terms (not shown). To
make the analysis more conclusive, we also uploaded the top 25 proteins and repeated
the analysis. However, this did not change the outcome considerably. A considerable
proportion of cathepsins led to a set of very similar terms that can be summarized as
lysosomal and peptidase aﬃliated processes.
IPA did not find enriched pathways in young mice, but found an enrichment of “Au-
tophagy”, “Phagosome Maturation” and “Macropinocytosis Signaling” associated pro-
teins in aged APPPS1 (Fig. 14).
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3.5 Shared and specific characteristics of aSyn and
APP transgenic mouse CSF
Combining results from both experiments revealed pathology-related changes in the
composition of the CSF proteome and facilitated discrimination of general neurode-
generation and neuroinflammation markers. We compared significance and direction of
protein changes between A30P-aSyn and APPPS1 datasets (Fig. 15). Interestingly we
found a correlative trend of up/up and down/down among the 550 proteins overlapping
from both datasets, indicating a more general and unspecific disease profile (Pearson
correlation, p < 0.0001). Among those were 24 proteins with p < 0.05 in both datasets,
representing CSF proteins altered in due to secondary events, such as neurodegeneration
or inflammation, but does not allow the two datasets -and respective pathologies- to be
distinguished (Fig. 15, green box). Aside from those, we also found 208 and 4 proteins
reflecting aSyn- or APPPS1-related CSF protein changes respectively (Fig. 15, yellow
and blue boxes). TREM2 was considerably altered in both models of b-amyloidosis and
synucleinopathies. The same can also be concluded for NfM, LAG3, various cathep-
sins, serpin A3N and complement C4B. Intriguingly, granulins had a considerably low
p-value in A30P-aSyn mice, but not in APPPS1 mice (see also Figs. 10 G & 13 G).
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Figure 15 – Specificity of CSF proteome alterations
Proteome changes in aSyn and APPPS1 were compared in order to assess pathology-specific proteins.
-log10 p-values (higher value = more significant) were transformed to negative values when the proteins
fold change was negative. Proteins with p1 & p2 < 0.05 (approximately 1.3 on -log10 scale) in both
datasets reflect general eﬀects present in both models of neurodegenerative diseases (green), while p1 <
0.05 and p2 > 0.05 of either of both datasets point protein alterations specific for either of the pathologies.
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Figure 16 – Proteins of the complement system enriched in A30P-aSyn CSF
Distinct increase in proteins from the complement system was observed in symptomatic A30-aSyn. In
aged APPPS1 mice only minor increases were observed.
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Another interesting outcome of matching both datasets is depicted in Figure 16. The
fold-change of complement-system associated proteins is shown for both models. A
noticeable 2-4 fold increase over the levels of controls was found for complements C1q
to C4-B in aged A30P-aSyn, but not in APPPS1.
3.6 LAG3 immunoblotting
As already highlighted by LC-MS measurements, LAG3 was clearly increased in aged
transgenics in both models under investigation (Figs. 10 E & 13 E). Its supposed con-
tribution in cell-to-cell transport of preformed a-synuclein fibrils made it a particularly
interesting target for validation of our MS datasets. For that purpose, we used antibody-
based western blot techniques (described in 2.5) and detected bands corresponding to
a molecular weight of 52-55 kDa, which were absent in CSF from a homozygous Lag3-
knockout mouse (Fig. 17). We therefore concluded that this signal stems from a 54 kDa
fragment of LAG3, termed soluble-LAG3 (sLAG3), which contains all extracellular do-
mains, but lacks the transmembrane and cytoplasmic domains. Quantification of the
signals detected in A30P-aSyn and corresponding controls (Fig. 17 A) revealed the
strongest diﬀerence in end-stage symptomatic A30P-aSyn, exceeding the average signal
detected in aged controls by a factor of 4. The diﬀerence to young mice of the same
genotype is even more obvious. A similar, but less pronounced trend is also present
in APPPS1 mice and controls (Fig. 17 B), where the intensities in aged APPPS1 are
doubled compared to controls of the same age. Consistently for both models, levels of
LAG3 tripled also during normal aging of control animals.
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Figure 17 – Levels of (soluble) LAG3 in CSF, determined by western blot
This antibody based method was used to validate LC-MS/MS based results and discriminate soluble LAG3
(54 kDa) from full length LAG3. Quantification of signals from A30P-aSyn (A) and APPPS1 (B) confirm
the quantitative outcome of the LC-MS/MS analysis. Diﬀerences between age groups, or transgenics and
WT of the same age group, were compared using Bonferroni’s post hoc test.
3.7 Neurofilament Light
This section is taken and/or adopted from the published manuscript (Bacioglu et al.,
2016).
In recent times, NfL has been increasingly discussed as CSF and blood biomarker
for the progression of neurodegenerative disorders. After analysis of the LC-MS/MS
proteome data, we aimed at an absolute measurement of CSF and serum NfL levels
in the examined mouse models and in an additional a-synuclein transgenic mouse line
expressing human A53T-mutated aSyn. This much more aggressive transgenic model
shows severe motor-symptoms already at 8-10 months of age.
In all three examined mouse models increased CSF NfL levels were already observed
in the intermediate age groups and plasma NfL levels reflected only 1/30–1/40 of CSF
levels (Fig. 18). Measurements of NfL in both, CSF and plasma, from A30P-aSyn mice
revealed a very robust age-related increase in magnitude similar to that of 6-8 month old
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A53T-aS mice. In the A53T-aSyn mice, a significant, more than 10-fold increase over
WT controls was already observed in non-symptomatic 2-4 month-old mice. Thereafter
NfL levels increased dramatically; in 8-10 month-old symptomatic mice NfL levels were
approximately 1.000-fold higher than in non-transgenic age-matched controls. Plasma
NfL did not yet exhibit a significant increase at 2–4 months of age, but a greater
than 100-fold increase was found in the A53T-aSyn mice at the symptomatic stage.
Consistently, such findings were also observed in APPPS1 mice with significantly higher
CSF NfL levels over non-tg controls at both 3 and 12 months of age. At 18 months
of age, the increase in APPPS1 mice was 10-fold over the age-matched WT controls.
Plasma NfL also increased compared to non-tg mice at 18 months of age (Figure 18).
However, the absolute NfL increase in APPPS1 was less than that observed in the A30P-
aSyn mice, which goes in line with the LC-MS/MS results, where NfL was exclusively
quantified in aged A30P-aSyn, the group with the highest amount of NfL (Fig. 10 H).
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Figure 18 – Increase of NfL in CSF and plasma of a-Syn and APP transgenic mice
(A) CSF NfL and (B) plasma NfL levels in A30P-aSyn, A53T-aSyn, APPPS1 and WT control mice
at diﬀerent ages. Diﬀerences between age groups or transgenics and WT of the same age group were
compared using Bonferroni’s post hoc test for multiple comparisons. Note the markedly elevated levels of
NfL in aged A30P-aSyn compared to APPPS1 mice of the same age. n = 4-6 mice per group, means ±
SEM are shown. Figure adapted from Bacioglu et al., 2016.
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Table 3 – Top 25 increased proteins in CSF of A30P-aSyn mice
log2 fold
change aSyn
/Control
-log10 p-value
aSyn vs
Control
Protein group Gene Protein
ID
18
mo
11
mo
3
mo
18
mo
11
mo
3
mo
Neurofilament medium Nefm P08553 10,6 0,1 8,8 0,0
Serine protease inhibitor A3N Serpina3n Q91WP6 4,4 0,5 0,5 8,6 0,7 1,3
Granulins Grn P28798 2,6 0,2 0,3 8,4 1,3 0,4
Complement C4 C4b P01029 2,5 0,5 0,5 7,5 2,2 1,6
Alpha-2-macroglobulin-P A2mp Q6GQT1 2,3 0,4 0,3 7,1 1,4 0,6
Triggering receptor expressed
on myeloid cells 2
Trem2 Q99NH8 3,7 0,9 6,8 1,1
Cathepsin B Ctsb P10605 2,7 0,4 0,4 6,8 1,8 1,2
YKL-40 / Chitinase-3-like
protein 1
Chi3l1 Q61362 1,9 0,2 0,1 6,3 0,5 0,1
Apolipoprotein E Apoe P08226 2,8 0,7 0,8 6,1 1,4 2,3
Complement C3 C3 P01027 2,0 0,3 0,4 6,0 0,5 0,9
Cathepsin Z Ctsz Q9WUU7 1,7 0,4 0,2 6,0 1,2 0,5
Apolipoprotein D Apod P51910 2,8 0,5 0,6 6,0 1,5 0,9
Gamma-enolase Eno2 P17183 3,6 0,7 -0,2 5,5 0,5 0,1
Lymphocyte antigen 86 Ly86 O88188 2,1 0,4 0,5 5,5 1,3 0,8
Beta-2-microglobulin B2m P01887 1,9 0,3 0,5 5,5 1,1 1,2
Nidogen-2 Nid2 O88322 1,6 0,3 0,7 5,4 0,6 2,2
Complement C1q subunit A C1qa P98086 2,1 0,2 0,2 5,4 0,5 0,4
Vitamin K-dependent protein
S
Pros1 Q08761 1,5 0,5 0,4 5,3 1,5 1,0
EGF-containing fibulin-like
extracellular matrix protein 2
Efemp2 Q9WVJ9 1,4 0,3 0,4 5,2 0,8 1,0
Lymphocyte activation gene
3 protein
Lag3 Q61790 1,8 0,1 0,2 5,2 0,3 0,2
Complement C1q
subcomponent subunit B
C1qb P14106 2,0 0,6 0,0 5,1 1,7 0,0
Olfactomedin-like protein 3 Olfml3 Q8BK62 1,8 0,6 0,0 5,1 1,1 0,0
Platelet-activating factor
acetylhydrolase
Pla2g7 Q60963 1,8 0,4 0,7 5,0 1,4 1,6
Plexin domain-containing
protein 2
Plxdc2 Q9DC11 1,3 0,2 0,3 4,9 0,3 0,5
Lysosomal
alpha-mannosidase
Man2b1 O09159 1,3 0,5 0,3 4,9 1,8 1,1
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Table 4 – Significantly decreased proteins in CSF of A30P-aSyn
log2 fold
change
aSyn/Control
-log10 p-value
aSyn vs
Control
Protein group Gene Protein
ID
18
mo
11
mo
3
mo
18
mo
11
mo
3
mo
Myosin light chain 1/3,
skeletal muscle isoform
Myl1 P05977 -1,6 -0,8 2,1 0,6
Cysteine-rich protein 1 Crip1 P63254 -1,4 -0,6 -0,3 1,9 1 0,4
Glycogen phosphorylase,
muscle form
Pygm Q9WUB3 -1,9 0,7 0,9 1,5 0,3 0,5
Carbonic anhydrase 3 Ca3 P16015 -1,6 0,6 -0,5 1,5 0,8 0,8
Parvalbumin alpha Pvalb P32848 -2 -0,7 -1,2 1,5 1,2 2,2
Creatine kinase M-type Ckm P07310 -1,9 0,7 -0,2 1,3 1,3 0,2
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Table 5 – Enrichment analysis of 220 significantly altered proteins in CSF from 18 month
old A30P-aSyn. Each category is ranked by EASE Score
Category Term Count % of
proteins
EASE Score
Cellular
Component
extracellular region 125 56,8 0,000012
lysosome 27 12,3 0,000044
blood microparticle 37 16,8 0,00013
extracellular exosome 158 71,8 0,00066
extracellular space 110 50 0,00073
basement membrane 17 7,7 0,0061
extracellular matrix 39 17,7 0,018
basal lamina 7 3,2 0,086
Biological
Process
innate immune response 24 10,9 0,011
proteolysis involved in cellular protein
catabolic process
9 4,1 0,024
extracellular matrix organization 14 6,4 0,039
tissue regeneration 5 2,3 0,053
proteolysis 23 10,5 0,055
immune system process 20 9,1 0,062
lipid metabolic process 12 5,5 0,073
inflammatory response 14 6,4 0,078
Molecular
Function
hydrolase activity 48 21,8 0,020
cysteine-type peptidase activity 8 3,6 0,027
hydrolase activity, acting on glycosyl
bonds
9 4,1 0,027
peptidase activity 24 10,9 0,045
serine-type carboxypeptidase activity 5 2,3 0,056
KEGG
Pathway
Lysosome 16 7,3 0,0066
Phagosome 9 4,1 0,03
Tuberculosis 9 4,1 0,03
ECM-receptor interaction 11 5 0,046
PI3K-Akt signaling pathway 17 7,7 0,071
Pertussis 10 4,5 0,08
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Figure 11 – Pathways altered in the CSF of A30P-aSyn
Pathways changed in the CSF of A30P-aSyn mice at diﬀerent ages. Up- or downregulation of the respective
protein subset is color-coded according to z-score.
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Table 6 – Top 25 altered proteins in CSF of APPPS1 mice
log2 fold change
in APPPS1 /
Controls
-log10 p-value
APPPS1 vs
Control
Protein name Gene Protein ID 18 mo 3 mo 18 mo 3 mo
Lysozyme C-2 Lyz2 P08905 1,7 0,6 5,8 1,3
Neurofilament medium
polypeptide
Nefm P08553 3,7 5,5
Cathepsin B Ctsb P10605 1,5 0,3 4,5 0,3
Lymphocyte activation gene 3
protein
Lag3 Q61790 1,6 0,0 4,4 0,0
Cathepsin Z Ctsz Q9WUU7 1,3 0,3 4,0 0,5
Serine protease inhibitor A3N Serpina3n Q91WP6 1,8 0,0 3,9 0,0
Cathepsin C; Dipeptidyl
peptidase 1
Ctsc P97821 2,2 -0,6 3,7 2,0
Triggering receptor expressed on
myeloid cells 2
Trem2 Q99NH8 2,2 3,2
Lysosomal alpha-mannosidase Man2b1 O09159 1,0 0,0 2,8 0,0
Lymphocyte antigen 86 Ly86 O88188 1,5 0,1 2,8 0,1
Complement C4 C4b P01029 1,2 0,0 2,7 0,0
Cathepsin L1 Ctsl P06797 0,8 0,1 2,5 0,2
Cathepsin S Ctss O70370 1,0 0,3 2,5 0,5
Monocyte diﬀerentiation
antigen CD14
Cd14 P10810 1,3 0,2 2,5 0,1
Cathepsin A; Lysosomal
protective protein
Ctsa P16675 1,5 -0,1 2,2 0,1
Ubiquitin Uba52;[...] P62984[...] 0,6 0,3 2,2 0,5
Iduronate 2-sulfatase Ids Q08890 0,9 -0,3 2,0 0,4
Unique cartilage
matrix-associated protein
Ucma Q14BU0 0,4 0,4 2,0 0,8
Adenylyl cyclase-associated
protein 1
Cap1 P40124 0,9 1,8
Protein S100-B S100b P50114 1,3 0,8 1,7 0,4
Superoxide dismutase [Cu-Zn] Sod1 P08228 0,7 0,2 1,6 0,3
N-acetylglucosamine-6-sulfatase Gns Q8BFR4 0,6 0,1 1,6 0,2
Cathepsin D Ctsd P18242 1,1 0,4 1,6 0,3
Alpha-2-macroglobulin-P A2mp Q6GQT1 0,7 0,2 1,5 0,3
Neuromodulin Gap43 P06837 1,8 0,1 1,5 0,2
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Figure 14 – Pathway altered in the CSF of APPPS1 at 18 months of age
Pathways changed in the CSF of APPPS1 mice at 18 months of age show a strong involvement of “Au-
tophagy” and “Phagosome Maturation” due to a strong deregulation of cathepsins. No enrichment clusters
were found at 3 months of age.
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Although this year marks the 200th anniversary of James Parkinson’s first description
of “the shaking palsy” and the 110th year after Alois Alzheimer’s initial report on Au-
guste Deter, researchers have yet not fully understood the underlying pathomechanisms
and prevention strategies remain to be found. Overlapping symptomatology and slow
progression of those and other neurodegenerative diseases further contribute to diag-
nostic diﬃculties and emphasize the need for specific biochemical markers (Blennow
et al., 2016). New approaches for the treatment of PD and AD would greatly profit
from novel and more reliable biomarkers that can facilitate diagnosis in early stages of
disease and tracking of its progression.
In AD research, the quest for respective biomarkers started only in 1995, when the first
enzyme-linked immunosorbent assays (ELISA) for Ab42, phosphorylated tau (P-tau)
and total tau (T-tau) protein were published (Blennow et al., 1995; Motter et al., 1995),
whereby a new field of research was born. Currently Ab42, P-tau and T-tau, due to
their interplay with the pathophysiological lesions, are still considered the most reliable
biomarkers for AD. Regarding PD, such biochemical markers remain to be found and
validated (Blennow et al., 2016).
Over the last years, numerous studies tried to identify novel biomarkers fulfilling the
criteria for clinical diagnosis. However, those studies typically focused on single can-
didates or small subsets of proteins and peptides, while the variety of sampling and
analysis procedures often led to conflicting results (Andersen et al., 2017). With the
technological progress of mass spectrometry-based proteomics, antibody-independent
methods were available and led to the development of the first fully validated single
reaction monitoring (SRM) mass spectrometry method for targeted quantification of
Ab42 (Leinenbach et al., 2014). Progress of MS-instrumentation also gave rise to a
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broader approach, the so-called shotgun proteomics, where complex mixtures of pro-
teins can be analyzed in an un-biased manner and result in quantification of several
hundreds or thousands of proteins, making it an ideal tool for the discovery of novel
biomarkers.
4.1 CSF proteome alterations
Mice are the most commonly used animal model in clinical research of neurological
diseases (Chesselet and Carmichael, 2012). As a result of a mutated human trans-
gene, the models used here recapitulate many aspects of disease. The resemblance to
transgenic protein deposition and core-biomarker changes in familial cases of PD and
AD is remarkable (Maia et al., 2013, 2015), which makes these mice suitable tools for
the investigation of protein dynamics in CSF and thereby search for altered molecular
processes and novel biomarkers of disease.
Hence the goals of this thesis were two-fold: First we wanted to quantify the CSF
proteome in an unbiased way to unveil alterations in proteins and biological processes
as a result of proteopathic lesions. Second, we sought to highlight both, common and
specific, -a-synucleinopathy or b-amyloidosis derived- changes and emphasize novel po-
tential biomarkers. Regarding the first goal, 1261 and 1168 proteins were identified in as
little as 2 µL CSF per technical replicate from A30P-aSyn and APPPS1 mice. This un-
derlines the remarkable sensitivity achieved by the label-free LC-ESI-MS/MS approach
for mouse CSF. The resulting datasets unveiled 220 protein groups in A30P-aSyn and
8 protein groups in APPPS1 with significantly altered levels at 18 months of age, when
protein deposition is clearly recognizable in both models. As anticipated, significant
changes were missing in the CSF proteome of 3 month old mice, which demonstrates
that the mere presence of the transgenic protein does not inevitably lead to substan-
tial proteome alterations. Concerning the second goal, our approach revealed a myriad
of proteins associated with neuroinflammation, the autophagy-lysosomal system and
other processes, but also shed light on proteins that may serve as novel biomarkers.
This emphasizes the value of aSyn and APP transgenic mouse models in the search for
new disease markers.
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4.2 CSF core biomarkers
a-synuclein The diagnostic value of aSyn has been investigated in many studies and
led to often conflicting results, while most studies report CSF total aSyn as being de-
creased in PD patients when compared to controls (Blennow et al., 2016). Intriguingly,
when compared to levels of young or presymptomatic mice, we measured 18-26 fold
increased levels of aSyn in the CSF of late-stage A30P-aSyn transgenic mice. At such
an advanced stage of disease, symptoms typically occur as a result of the death of
dopaminergic neurons in the substantia nigra (Parkkinen et al., 2008; Blennow et al.,
2016), which in turn leads to a release of intracellular oligomeric aSyn. Due to tryptic
digestion, which is essential for a shotgun mass-spec based approach, the experimen-
tal setup can not diﬀerentiate between the various aSyn species, such as monomers or
oligomers. We must therefore assume that oligomeric aSyn gets digested by trypsin
and thereby boosts the amount of aSyn peptides quantified by MS. The aSyn peptides
detected in 11mo WT animals either originate from carry-over of prior LC runs, are
artifacts of the match between runs algorithm, or simply reflect murine aSyn. Murine
aSyn was not discriminated from A30P-human aSyn due to a high degree of homology.
APP We were able to distinguish between the endogenous murine APP and the trans-
genic APP with the Swedish mutation (APPswe) expressed in APPPS1 mice. As a
proof of concept, we detected relatively stable levels of the murine APP over age, but
also similar expression levels in the control animals. The analysis also revealed that
APPswe-derived peptides were exclusively quantified in CSF from APPPS1 mice and
that the levels were not influenced by the age of the transgenic mice.
Tau Although the microtubule-associated protein tau is considered a core biomarker
for AD, we did not quantify it in the model of b-amyloidosis. Also one would not
necessarily expect to find substantial levels of tau in a model of b-amyloidosis, spared
from considerable tau-pathology and NFTs . Nevertheless, we exclusively quantified
tau protein in three of the symptomatic A30P-aSyn mice. Tau is known to bind aSyn
and positive correlation between CSF aSyn and tau levels has been observed (Jensen
et al., 1999; Slaets et al., 2014), which might explain its CSF abundance in aged aSyn-
overexpressing mice.
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4.3 Inflammatory proteins
Microglial activation and neuroinflammation are increasingly recognized to play critical
roles in the pathogenesis of PD, AD and other neurodegenerative diseases (Amor et al.,
2010; Tansey and Goldberg, 2010; Heneka et al., 2015). Whether the activation of
microglia is beneficial or adverse for the course of disease is still an open question
(reviewed in greater detail in Frank-Cannon et al., 2009). In the work presented here
we show that neuroinflammation is also reflected in the CSF proteome composition of
transgenic mouse models.
Serpin A3N We found a remarkable increase in serine protease inhibitor A3N (Serpin
A3N), the murine orthologue of human a1-antichymotrypsin (ACT) (Horvath et al.,
2005) in both models at 18 months of age. ACT is a well established marker of in-
flammation; co-localized with amyloid-b in senile plaques (Abraham et al., 1988) and
elevated levels were reported in CSF and plasma of AD patients (Licastro et al., 1995;
Porcellini et al., 2008). Genetic association studies have come to conflicting results
concerning the connection of ACT gene polymorphism and susceptibility for PD, but
the age of disease onset seems to be influenced by ACT (Yamamoto et al., 1997; Wang
et al., 2001). These findings, together with our results, propose an unspecific and
inflammation-derived role for Serpin A3N, as a consequence of proteopathic deposition.
Granulin / Progranulin Strikingly, granulins (GRN) were increased in the A30P-
aSyn dataset, but not in APPPS1 CSF. Granulins are cleaved from its precursor protein
progranulin (PGRN) and typically involved in cellular processes such as wound healing
and inflammation (He et al., 2003). In humans, PGRN mutations are a major inher-
ited cause of frontotemporal dementia (FTD), and mutation-caused PGRN deficiency
promotes neuroinflammation (Baker et al., 2006; Cruts et al., 2006; Martens et al.,
2012). Intriguingly, mutations in PGRN were described in some rare cases of AD and
PD (Brouwers et al., 2007, 2008; Kelley et al., 2010). PGRN is also connected to the
dopaminergic system in mice, having a protective function for dopaminergic neurons,
while PGRN deficiency promotes deregulated microglial activation and contributes to
increased neuronal loss (Martens et al., 2012; Van Kampen et al., 2014). Further ex-
periments are needed to identify the molecular mechanism underlying CSF granulin
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increase observed in our mouse model of a-synucleinopathy, while it is likely linked to
the dopaminergic system.
Complement system We also found increased levels of complement related proteins
in A30P-aSyn CSF. The complement system is part of both, innate and adaptive im-
mune system, while its inappropriate activation can contribute to disease (Mackay et al.,
2001). Furthermore, Magdalinou and colleagues recently found marked increases of
complement C9 and complement factor H in the CSF of PD patients (Magdalinou
et al., 2017). However, they did not report an increase in other complement compo-
nents, which are altered in A30P-aSyn, but not in APPPS1.
TREM2 While triggering receptor expressed on myeloid cells 2 (TREM2) has been
intensively investigated as biomarker for AD (Guerreiro et al., 2013; Kleinberger et al.,
2014; Suárez-Calvet et al., 2016), others highlight its role in inflammation and mi-
croglial activation (Hickman and El Khoury, 2014). TREM2 has been shown to be
upregulated on amyloid-plaque-associated microglia in depositing APP23 mice, another
APP-transgenic model for b-amyloidosis (Frank et al., 2008). We found considerably
elevated levels of TREM2 in the CSF of both models and thereby characterize TREM2
as a general CSF marker for neuroinflammation or -degeneration, rather than a specific
marker for amyloid-deposition.
4.4 LAG3
Mao et al. recently described lymphocyte activation gene 3 protein (LAG3) as a protein
facilitating binding and transmission of preformed a-synuclein fibrils (PFF) on neurons.
They also demonstrated a high specificity of LAG3 binding to aSyn-PFF (Mao et al.,
2016). Intriguingly, our study shows increased levels of LAG3 not only in aSyn mice,
but also in APPPS1 mice, devoid of any a-synucleinopathy. We therefore assume an
aSyn-independent mechanism causing an increase of LAG3-derived peptides in CSF.
LAG3 can be cleaved by a-secretases ADAM10 and ADAM17, resulting in a 16-kDa
transmembrane and a 54-kDa fragment containing all extracellular domains while the
54-kDa fragment is released as soluble LAG3 (sLAG3) upon T-cell activation (Lammich
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et al., 1999; Li et al., 2004). This matches the molecular weight of the signal detected
in murine CSF on western blot. The quantitative results of both LC-ESI-MS/MS
experiments were validated by western blot analysis of LAG3, hence demonstrating a
high correlation of sLAG3 levels determined by immunoblotting and mass spectrometry.
4.5 Lysosomal proteins
Impairment of the autophagy-lysosomal pathway is increasingly regarded as a major
pathogenic event in neurodegenerative diseases, including PD (Dehay et al., 2013). Our
analysis revealed a high fraction of lysosomal proteins enriched in A30P-aSyn CSF,
including 3-fold increased levels of phospholipase D3 (PLD3). However, in APPPS1
we did not measure such an increase, while others demonstrated inverse correlations
of PLD3 expression with APP expression or Ab-production in vitro (Cruchaga et al.,
2014a). Furthermore, mutations in Pld3 confer risk to AD and an in-vitro knockdown
leads to an increase of extracellular Ab42 and Ab40, while PLD3 was furthermore found
to accumulate in senile plaques (Cruchaga et al., 2014b; Satoh et al., 2014). Fazzari and
colleagues recently challenged PLD3 implication in APP metabolism or plaque-burden
and emphasized its localization and implication in the lysosomal system suggesting
alternative functions for PLD3 in neurodegeneration (Fazzari et al., 2017).
Lysosomal malfunction accompanies aSyn aggregation and is increasingly recognized as
key part in pathogenesis of many neurodegenerative diseases, including PD (Meredith
et al., 2002; Pan et al., 2008). Cathepsins, lysosomal alpha-mannosidase (Man2b1) and
N-acetylglucosamine-6-sulfatase (Gns) are examples of lysosomal proteins deregulated
in CSF of both models used in this study. Considering the marked increase of PLD3
in A30P-aSyn CSF and the rather unspecific elevation of other lysosomal proteins, our
data support the concept of a disturbed lysosomal system as a result of proteopathic
lesions.
4.6 CART
Motivated by the idea to find biomarkers that would cover the urgent need for early
biomarkers of PD, we also analyzed presymptomatic A30P-aSyn mice, which have aSyn
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deposition predominantly in the brainstem and spinal cord, but lack noticeable motor-
symptoms, thereby mimicking PD patients in early stages of disease. Peptides derived
from cocaine- and amphetamine-regulated transcript protein (CART) were elevated in
CSF of presymptomatic aSyn mice, while being reduced to WT levels in symptomatic
mice. CART is involved in various physiological processes mediated by dopamine, while
administration of CART was shown to ameliorate dopaminergic neuronal loss in models
of PD (Mao et al., 2013; Subhedar et al., 2014; Upadhya et al., 2016). While CSF CART
levels were reduced by 30% in cases of dementia with Lewy bodies (DLB) (Schultz et al.,
2009), we report the amount of CART to be doubled in the CSF of A30P-aSyn mice
at 11 months of age. The exact mechanism influencing CART-level fluctuations in the
CSF remains to be identified.
4.7 Synaptic proteins
Synaptic dysfunction represents a major event in PD, which is likely a consequence of
abnormal aSyn aggregation. In a healthy physiological state, aSyn is a natively un-
folded monomer involved in maintenance of neurotransmitter homeostasis by regulat-
ing vesicle fusion, clustering and traﬃcking via SNARE complexes, thereby proposing
synapses as the primarily aﬀected site in case of aSyn pathology (Calo et al., 2016;
Blennow et al., 2016). SNARE-complexes are formed from synaptobrevin, syntaxin
and SNAP-25 (Chandra et al., 2005; Burre et al., 2010). In this study we were able
to quantify SNAP-25 and syntaxin-1B, the isoform of syntaxin necessary for the reg-
ulation of synaptic vesicle exocytosis (Mishima et al., 2014). However, SNAP-25 and
syntaxin-1B were detected almost exclusively in the CSF of aged A30P-aSyn, while
the few quantification events in younger mice are based on error-prone “match between
runs” identification. It is also a valid assumption that the levels of both proteins were
below detection limit in controls and younger A30P-aSyn mice. A recent study also
reported a disease specific overall increase of SNAP-25 in CSF of PD patients related to
cognitive and motor symptom severity (Bereczki et al., 2017). We can therefore assume
that synaptic dysfunction is also occurring in our mouse models of a-synucleinopathy
and that synaptic proteins, such as SNAP-25 and syntaxin-1B may potentially serve
as future diagnostic biomarkers or predictive factors for the progression to dementia in
PD (Blennow et al., 2016).
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4.8 Neurofilament light
As the proteome dataset demonstrated, neurofilaments, such as a-internexin, neurofil-
aments light (NfL), medium (NfM) and heavy (NfH), are markedly increased in symp-
tomatic A30P-aSyn and aged APPPS1 mice. From the group of neurofilaments, we
chose NfL to confirm the increase not only in CSF, but also in plasma. We additionally
used a third mouse-model, expressing the A53T-mutated form of human a-synuclein,
to emphasize the link between aSyn deposits and NfL levels in CSF and blood.
We used a validated NfL assay (Gaiottino et al., 2013) adapted for murine samples
and small volumes and therewith confirmed increased NfL levels in CSF and in blood
of mouse models for b-amyloidosis and a-synucleinopathies. In all three models, the
increase occurred at the same age as the respective brain lesions became apparent.
Elevated CSF and blood NfL levels were recently also found in patients with a-synuclein-
opathies, tauopathies and b-amyloidosis (Zetterberg et al., 2015; Rohrer et al., 2016),
which not only makes NfL an easily accessible blood biomarker, but also endorses the
translational value of our mouse models. The study further demonstrated that neither
CSF nor blood NfL increases are specific for aggregated aSyn, tau or b-amyloid. In
turn, this means that the observed NfL boost stems from a downstream, or secondary,
event in neurodegeneration. As neurofilaments play a key role in axonal stabilization
and function as integral components of synapses, an increase in NfL blood or CSF
levels is thought to reflect NfL release upon neuronal injury, axonal degeneration and
synapse loss (Lee and Cleveland, 1996; Petzold, 2005; Yuan et al., 2015), all of which
have been observed in aSyn and amyloid-b transgenic mice (van der Putten et al.,
2000; Phinney et al., 2003; Wirths et al., 2006). The more pronounced increase of
NfL in aSyn transgenic models, compared to APPPS1 mice, may be caused by a faster
and more pronounced protein deposition and accumulation predominantly in brainstem
and spinal cord. Both areas harbor thick-caliber myelinated motor neurons, rich in NfL
(Petzold, 2005; Yuan et al., 2012). Consistently, CSF NfL levels of patients suﬀering
from amyotrophic lateral sclerosis (ALS), a motor neuron-specific disease, are notably
higher than in AD patients (Gaiottino et al., 2013). Albeit the exact mechanism by
which NfL gets released into the CSF remains obscure, we can assume that the NfL-
stock in blood is derived from the CSF. This is not only because neurofilaments are
synthesized in the central nervous system, which is in closer contact to CSF than blood,
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but also by the observation, that all three models show a more prominent and earlier
NfL increase in CSF than in blood.
Despite the focus on NfL, the proteome dataset demonstrates that other neurofilament
subunits may also be suited as CSF and blood marker of proteopathic neurodegenerative
diseases. NfM, for example, was also found to be elevated in plasma and CSF of ALS
and FTD patients (Pijnenburg et al., 2007; Häggmark et al., 2014). Nevertheless, NfL
has proven to be an easily accessible blood biomarker that can be used to track CNS
neurodegeneration and may serve as progression and treatment response marker for
human neurodegenerative diseases.
4.9 Comparison to human CSF proteome studies
Another part of this work was the comparison of the murine CSF proteome datasets to
published studies with similar proteomic approaches in human patients and neurologi-
cally healthy controls.
For PD, only few such studies have been conducted within the last years (Abdi et al.,
2006; Zhang et al., 2008; Constantinescu et al., 2010; Ishigami et al., 2012; Lehnert
et al., 2012; Magdalinou et al., 2017) and singling out promising candidate markers
has generally proven to be diﬃcult (Magdalinou et al., 2017). For the comparison, we
focused on the most recent and technically most similar work published recently by
Magdalinou and colleagues. The comparison of the A30P-aSyn dataset and their 27
significant hits demonstrates the high degree of similarity of our findings with results
obtained from patients suﬀering from PD and atypical parkinsonian syndromes (APS).
Of 27 hits, 25 could be translated to respective murine proteins of which 21 were
also quantified in our mouse dataset. Intriguingly, four out of six hits being increased
in PD and APS patients were also significantly elevated in the CSF of A30P-aSyn
mice: Serine protease inhibitor A3N (Serpin A3N), chitinase-3-like protein 1 (YKL-
40), complement factor H and zinc-alpha-2-glycoprotein. The remaining 15 proteins
identified were unaﬀected in our mouse model. However, the same general cellular
processes were found in patients and mice, namely inflammation markers and synaptic
proteins.
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Much of the CSF proteome work on AD has focused on the core biomarkers, T-tau,
P-tau and Ab42, while unbiased shotgun approaches are less common. The most com-
prehensive shotgun study of the last years is probably the work of Khoonsari et al.,
2016. Despite similar instruments and analysis in MaxQuant, the overlap with the
APPPS1 dataset is rather poor. Of 85 diﬀerentially altered proteins in the Khoonsari
dataset, 61 were converted to the murine homologous proteins and matched to our
dataset. Amongst those, only lysozyme C-2 and serpin A3N were significantly altered
in both studies. However, in contrast to our results, they reported reduced levels of
these proteins. Nevertheless, this is not very surprising, as one must note that AD
patients included in the study were already at a late stage of disease, whereas APPPS1
mice model Ab deposition, an early event in the cascade of AD pathology. Surprisingly,
neither neurofilaments nor TREM2 were amongst the significant hits described in the
human study.
4.10 Pathology specific and unspecific protein
changes
In order to highlight specific CSF proteome alterations resulting from aSyn proteopathic
lesions and discriminate these changes from general neurodegenerative processes, which
would also occur in models of b-amyloidosis, we compared the CSF proteome from
A30P-aSyn and APPPS1 mice (see 3.5). Amongst 24 unspecific proteins (with p-values
< 5%) we found a clear representation of inflammatory and microglia-related proteins.
While we identified 208 A30P-aSyn specific proteins, we only found 4 proteins specific
for APPPS1. The diﬀerence in numbers might be due to diﬀerences in the severity of
pathology at 18 months of age. While APPPS1 mice aged 18 months are in a generally
good condition, A30P-aSyn mice exhibit motor-symptoms and worse overall health
condition.
In conclusion, we were able to quantify hundreds of proteins in CSF from aSyn and
APPPS1 transgenic mouse models, granting deep insight in PD- and AD-associated
CSF protein changes. The sheer number of proteins identified overlapping with PD and
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AD literature, emphasizes the value and utility of transgenic mouse models especially
in the context of CSF biomarkers and highlights the strong implication of neuroinflam-
matory processes and the lysosomal system in a-synucleinopathies. The datasets at
hand will be a helpful reference for future CSF biomarker research in PD and AD.
57
Bibliography
Abdi, F., Quinn, J. F., Jankovic, J., McIntosh, M., Leverenz, J. B., Peskind, E., Nixon, R.,
Nutt, J., Chung, K., Zabetian, C., Samii, A., Lin, M., Hattan, S., Pan, C., Wang, Y.,
Jin, J., Zhu, D., Li, G. J., Liu, Y., Waichunas, D., Montine, T. J., and Zhang, J. (2006).
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal
fluid of patients with neurodegenerative disorders. Journal of Alzheimer’s disease : JAD,
9(3):293–348.
Abraham, C. R., Selkoe, D. J., and Potter, H. (1988). Immunochemical identification of the ser-
ine protease inhibitor alpha1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s
disease. Cell, 52(4):487–501.
Aebersold, R. and Mann, M. (2003). Mass spectrometry-based proteomics. Nature,
422(6928):198–207.
Alzheimer, A. (1907). Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeits Psychiatry
Psychisch Y Gerichtlich Med, 64:146–8.
Alzheimer’s Association (2013). 2013 Alzheimer’s disease facts and figures. Alzheimer’s and
Dementia, 9(2):208–245.
Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in neurodegen-
erative diseases. Immunology, 129(2):154–169.
Andersen, A. D., Binzer, M., Stenager, E., and Gramsbergen, J. B. (2017). Cerebrospinal fluid
biomarkers for Parkinson’s disease - a systematic review. Acta Neurologica Scandinavica,
135(1):34–56.
Antony, P. M. A., Diederich, N. J., and Balling, R. (2011). Parkinson’s disease mouse models
in translational research. Mammalian Genome, 22(7-8):401–419.
Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir,
D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J. O., Rajput, A., Rajput, A. H., Jon
Stoessl, A., and Farrer, M. J. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation
for Parkinson’s disease. Movement Disorders, 28(6):811–813.
58
Bibliography
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser,
M., Eninger, T., Lambert, M., Pilotto, A., Shimshek, D. R., Neumann, U., Kahle, P. J.,
Staufenbiel, M., Neumann, M., Maetzler, W., Kuhle, J., and Jucker, M. (2016). Neurofil-
ament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models
and in Neurodegenerative Diseases. Neuron, 91(1):56–66.
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C.,
Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., Cannon, A., Dwosh, E., Neary,
D., Melquist, S., Richardson, A., Dickson, D., Berger, Z., Eriksen, J., Robinson, T., Zehr,
C., Dickey, C. A., Crook, R., McGowan, E., Mann, D., Boeve, B. F., Feldman, H. H., and
Hutton, M. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia
linked to chromosome 17. Nature, 442(7105):916–919.
Bantscheﬀ, M., Schirle, M., Sweetman, G., Rick, J., and Kuster, B. (2007). Quantitative
mass spectrometry in proteomics: A critical review. Analytical and Bioanalytical Chemistry,
389(4):1017–1031.
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson,
P., and Aarsland, D. (2017). Synaptic proteins in CSF relate to Parkinson’s disease stage
markers. npj Parkinson’s Disease, 3(1):7.
Blennow, K., Biscetti, L., Eusebi, P., and Parnetti, L. (2016). Cerebrospinal fluid biomarkers in
Alzheimer’s and Parkinson’s diseases-From pathophysiology to clinical practice. Movement
Disorders, 31(6):836–847.
Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 6(3):131–144.
Blennow, K., Wallin, A., and Agren, H. (1995). tau Protein in Cerebrospinal Fluid. A Bio-
chemical Marker. Molecular and Chemical Neuropathology, 26(3):231–245.
Blennow, K., Wallin, A., and Ekman, R. (1994). Neuron specific enolase in cerebrospinal fluid:
A biochemical marker for neuronal degeneration in dementia disorders? Journal of Neural
Transmission - Parkinson’s Disease and Dementia Section, 8(3):183–191.
Braak, H. and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathologica, 82(4):239–259.
Braak, H. and Braak, E. (1995). Staging of alzheimer’s disease-related neurofibrillary changes.
Neurobiology of Aging, 16(3):271–278.
Braak, H. and Del Tredici, K. (2009). Neuroanatomy and pathology of sporadic Parkinson’s
disease. Advances in anatomy, embryology, and cell biology, 201:1–119.
59
Bibliography
Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A. I., Jansen Steur, E. N. H., and Braak, E.
(2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of
Aging, 24(2):197–211.
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen,
C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris,
J. C., Benzinger, T. L., and Ances, B. M. (2016). Tau and A-beta imaging, CSF measures,
and cognition in Alzheimer’s disease. Science Translational Medicine, 8(338):1–10.
Brooks, D. J. (2010). Imaging Approaches to Parkinson Disease. Journal of Nuclear Medicine,
51(4):596–609.
Brouwers, N., Nuytemans, K., van der Zee, J., Gijselinck, I., Engelborghs, S., Theuns, J.,
Kumar-Singh, S., Pickut, B. a., Pals, P., Dermaut, B., Bogaerts, V., De Pooter, T., Serneels,
S., Van den Broeck, M., Cuijt, I., Mattheijssens, M., Peeters, K., Sciot, R., Martin, J.-J.,
Cras, P., Santens, P., Vandenberghe, R., De Deyn, P. P., Cruts, M., Van Broeckhoven, C.,
and Sleegers, K. (2007). Alzheimer and Parkinson diagnoses in progranulin null mutation
carriers in an extended founder family. Archives of neurology, 64(10):1436–1446.
Brouwers, N., Sleegers, K., Engelborghs, S., Maurer-Stroh, S., Gijselinck, I., Van Der Zee,
J., Pickut, B. A., Van Den Broeck, M., Mattheijssens, M., Peeters, K., Schymkowitz, J.,
Rousseau, F., Martin, J. J., Cruts, M., De Deyn, P. P., and Van Broeckhoven, C. (2008). Ge-
netic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease.
Neurology, 71(9):656–664.
Buerger, K., Ewers, M., Pirttilä, T., Zinkowski, R., Alafuzoﬀ, I., Teipel, S. J., DeBernardis, J.,
Kerkman, D., McCulloch, C., Soininen, H., and Hampel, H. (2006). CSF phosphorylated tau
protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain,
129(11):3035–3041.
Burns, A. and Iliﬀe, S. (2009). Alzheimer’s disease. BMJ, 338(feb05 1):b158–b158.
Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., and Sudhof, T. C.
(2010). alpha-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. Science,
329(5999):1663–1667.
Calo, L., Wegrzynowicz, M., Santivanez-Perez, J., and Grazia Spillantini, M. (2016). Synaptic
failure and alpha-synuclein. Movement Disorders, 31(2):169–177.
Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M., and Sudhof, T. C.
(2005). alpha-synuclein cooperates with CSP alpha in preventing neurodegeneration. Cell,
123(3):383–396.
60
Bibliography
Chesselet, M.-F. and Carmichael, S. T. (2012). Animal Models of Neurological Disorders.
Neurotherapeutics, 9(2):241–244.
Clarke, C. E. and Moore, A. P. (2007). Parkinson’s disease. BMJ clinical evidence, 2007.
Compta, Y., Valente, T., Saura, J., Segura, B., Iranzo, Á., Serradell, M., Junqué, C., Tolosa,
E., Valldeoriola, F., Muñoz, E., Santamaria, J., Cámara, A., Fernández, M., Fortea, J.,
Buongiorno, M., Molinuevo, J. L., Bargalló, N., and Martí, M. J. (2014). Correlates of cere-
brospinal fluid levels of oligomeric- and total-↵-synuclein in premotor, motor and dementia
stages of Parkinson’s disease. Journal of Neurology, 262(2):294–306.
Constantinescu, R., Andreasson, U., Li, S., Podust, V. N., Mattsson, N., Anckarsäter, R.,
Anckarsäter, H., Rosengren, L., Holmberg, B., Blennow, K., Wikkelsö, C., Rüetschi, U., and
Zetterberg, H. (2010). Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.
Parkinsonism and Related Disorders, 16(8):545–549.
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., and Mann, M. (2014). Accurate
proteome-wide label-free quantification by delayed normalization and maximal peptide ratio
extraction, termed MaxLFQ. Molecular Cellular Proteomics MCP, 13(9):2513–2526.
Cox, J. and Mann, M. (2012). 1D and 2D annotation enrichment: a statistical method inte-
grating quantitative proteomics with complementary high-throughput data. BMC Bioinfor-
matics, 13(Suppl 16):S12.
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., ..., Kauwe, J. S. K., and Goate, A. M.
(2014a). Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s
disease. Nature, 505(7484):550–4.
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B.,
Jeng, A. T., Skorupa, T., Carrell, D., Bailey, M., Mckean, D., Shulman, J. M., and De, P. L.
(2014b). GWAS of cerebrospinal fluid tau levels identifies novel risk variants for Alzheimer’s
disease. Neuron, 78(2):256–268.
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers,
R., Vandenberghe, R., Dermaut, B., Martin, J. J., van Duijn, C., Peeters, K., Sciot, R.,
Santens, P., De Pooter, T., Mattheijssens, M., Van den Broeck, M., Cuijt, I., Vennekens,
K., De Deyn, P. P., Kumar-Singh, S., and Van Broeckhoven, C. (2006). Null mutations in
progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.
Nature, 442(August):920–924.
de Lau, L. M. and Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. Lancet
Neurology, 5(6):525–535.
61
Bibliography
De Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa,
S., Manubens-Bertran, J. M., Alpérovitch, A., and Rocca, W. A. (1997). Prevalence of
parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative
Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease.
Journal of neurology, neurosurgery, and psychiatry, 62(1):10–5.
De Strooper, B. (2007). Loss-of-function presenilin mutations in Alzheimer disease. Talking
Point on the role of presenilin mutations in Alzheimer disease. EMBO reports, 8(2):141–146.
De Strooper, B. and Annaert, W. (2010). Novel Research Horizons for Presenilins and gamma-
Secretases in Cell Biology and Disease. Annual review of cell and developmental biology,
(June):1–26.
Dehay, B., Martinez-Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R.,
Klein, C., Vila, M., and Bezard, E. (2013). Lysosomal impairment in Parkinson’s disease.
Movement Disorders, 28(6):725–732.
Duﬀ, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L.,
Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B.,
Hardy, J., and Younkin, S. (1996). Increased amyloid- 42(43) in brains of mice expressing
mutant presenilin 1. Nature, 383(6602):710–713.
Durbin, K. R., Fornelli, L., Fellers, R. T., Doubleday, P. F., Narita, M., and Kelleher, N. L.
(2016). Quantitation and Identification of Thousands of Human Proteoforms below 30 kDa.
Journal of Proteome Research, 15(3):976–982.
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, a. R., Oltersdorf, T., McClure,
D., and Ward, P. J. (1990). Cleavage of amyloid beta peptide during constitutive processing
of its precursor. Science, 248(4959):1122–1124.
Fazzari, P., Horre, K., Arranz, A. M., Frigerio, C. S., Saito, T., Saido, T. C., and De Strooper,
B. (2017). PLD3 gene and processing of APP. Nature, 541(7638):E1–E2.
Fearnley, J. M. and Lees, A. J. (1991). Ageing and Parkinson’s Disease: Substantia Nigra
Regional Selectivity. Brain, 114(5):2283–2301.
Fernagut, P.-O. and Chesselet, M.-F. (2004). Alpha-synuclein and transgenic mouse models.
Neurobiology of disease, 17(2):123–130.
Ferreira, M. and Massano, J. (2017). An updated review of Parkinson’s disease genetics and
clinicopathological correlations. Acta Neurologica Scandinavica, 135(3):273–284.
Forno, L. S. (1996). Neuropathology of Parkinson’s Disease. Journal of Neuropathology amp;
Experimental Neurology, 55(3):259 LP – 272.
62
Bibliography
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., and Deller,
T. (2008). TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23
transgenic mice. Glia, 56(13):1438–1447.
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., and Tansey, M. G. (2009). Does neu-
roinflammation fan the flame in neurodegenerative diseases? Molecular Neurodegeneration,
4(1):47.
Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick,
J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L., Kappos, L., Leppert, D., Petzold, A.,
Giovannoni, G., and Kuhle, J. (2013). Increased Neurofilament Light Chain Blood Levels
in Neurodegenerative Neurological Diseases. PLoS ONE, 8(9):1–9.
Gibb, W. R. and Lees, A. J. (1988). The relevance of the Lewy body to the pathogenesis of
idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery Psychiatry, 51(6):745–
752.
Glenner, G. G. and Wong, C. W. (1984a). Alzheimer’s disease and Down’s syndrome: Sharing
of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research
Communications, 122(3):1131–1135.
Glenner, G. G. and Wong, C. W. (1984b). Alzheimer’s disease: Initial report of the purification
and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical
Research Communications, 120(3):885–890.
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuﬀra,
L., Haynes, A., Irving, N., and James, L. (1991). Segregation of a missense mutation in the
amyloid precursor protein gene with familial Alzheimer’s disease. Nature, 349(6311):704–6.
Goedert, M. and Spillantini, M. G. (2006). A Century of Alzheimer’s Disease. Science,
314(5800):777–781.
Goedert, M., Spillantini, M. G., Del Tredici, K., and Braak, H. (2013). 100 years of Lewy
pathology. Nature Reviews Neurology, 9(1):13–24.
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., and Klug, A. (1988). Cloning and
sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer
disease: identification as the microtubule-associated protein tau. Proceedings of the National
Academy of Sciences of the United States of America, 85(11):4051–5.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y.-C., Zaidi, M. S., and Wisniewski, H. M.
(1986a). Microtubule-associated protein tau. A component of Alzheimer paired helical fila-
ments. Journal of Biological Chemistry, 261(13):6084—-6089.
63
Bibliography
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder,
L. I. (1986b). Abnormal phosphorylation of the microtubule-associated protein tau (tau)
in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences,
83(13):4913–4917.
Guerreiro, R., Ph, D., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E.,
Cruchaga, C., Kauwe, J. S. K., Younkin, S., Hazrati, L., Lambert, J.-c., Amouyel, P.,
Goate, A., Singleton, A., Hardy, J., and Alzheimer, T. (2013). TREM2 variants in AD. New
England Journal of Medicine, 368(2):117–127.
Haass, C., Kaether, C., Thinakaran, G., and Sisodia, S. (2012). Traﬃcking and proteolytic
processing of APP. Cold Spring Harbor Perspectives in Medicine, 2(5).
Häggmark, A., Mikus, M., Mohsenchian, A., Hong, M.-G., Forsström, B., Gajewska, B.,
Barańczyk-Kuźma, A., Uhlén, M., Schwenk, J. M., Kuźma-Kozakiewicz, M., and Nilsson, P.
(2014). Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis.
Annals of clinical and translational neurology, 1(8):544–53.
Halbgebauer, S., Nagl, M., Klafki, H., Haußmann, U., Steinacker, P., Oeckl, P., Kassubek,
J., Pinkhardt, E., Ludolph, A. C., Soininen, H., Herukka, S.-K., Wiltfang, J., and Otto,
M. (2016). Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of
baseline data. Scientific reports, 6:26145.
Hamley, I. W. (2012). The amyloid beta peptide: A chemist’s perspective. role in Alzheimer’s
and fibrillization. Chemical Reviews, 112(10):5147–5192.
Hampel, H., Mitchell, A., Blennow, K., Frank, R. A., Brettschneider, S., Weller, L., and
Möller, H. J. (2004). Core biological marker candidates of Alzheimer’s disease - Perspectives
for diagnosis, prediction of outcome and reflection of biological activity. Journal of Neural
Transmission, 111(3):247–272.
Hardy, J. and Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of
Alzheimer’s disease. Trends in Pharmacological Sciences, 12(C):383–388.
Hardy, J. and Higgins, G. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Sci-
ence, 256(5054):184–185.
He, Z., Ong, C. H., Halper, J., and Bateman, A. (2003). Progranulin is a mediator of the
wound response. Nature Medicine, 9(2):225–229.
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., ..., and Kummer,
M. (2015). Neuroinflammation in Alzheimer’s disease. The Lancet Neurology, 14(4):388–405.
64
Bibliography
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E.,
and Blennow, K. (2001). Transient increase in total tau but not phospho-tau in human
cerebrospinal fluid after acute stroke. Neuroscience Letters, 297(3):187–190.
Hickman, S. E. and El Khoury, J. (2014). TREM2 and the neuroimmunology of Alzheimer’s
disease. Biochemical Pharmacology, 88(4):495–498.
Hiltunen, M., van Groen, T., and Jolkkonen, J. (2009). Functional roles of amyloid-beta
protein precursor and amyloid-beta peptides: evidence from experimental studies. Journal
of Alzheimer’s disease : JAD, 18(2):401–12.
Hipkiss, A. R. (2006). Accumulation of altered proteins and ageing: Causes and eﬀects.
Experimental Gerontology, 41(5):464–473.
Horvath, A. J., Irving, J. A., Rossjohn, J., Law, R. H., Bottomley, S. P., Quinsey, N. S.,
Pike, R. N., Coughlin, P. B., and Whisstock, J. C. (2005). The murine orthologue of
human antichymotrypsin: A structural paradigm for clade A3 serpins. Journal of Biological
Chemistry, 280(52):43168–43178.
Huang, D. W., Lempicki, R. a., and Sherman, B. T. (2009a). Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1):44–
57.
Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009b). Bioinformatics enrichment
tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids
Research, 37(1):1–13.
Hühmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N., and Harrington, M. G. (2006).
Protein Analysis in Human Cerebrospinal Fluid: Physiological Aspects, Current Progress
and Future Challenges. Disease Markers, 22(1-2):3–26.
Ikeuchi, T., Kakita, A., Shiga, A., Kasuga, K., Kaneko, H., Tan, C.-F., Idezuka, J., Wak-
abayashi, K., Onodera, O., Iwatsubo, T., Nishizawa, M., Takahashi, H., and Ishikawa, A.
(2008). Patients homozygous and heterozygous for SNCA duplication in a family with
parkinsonism and dementia. Archives of neurology, 65(4):514–9.
Ishigami, N., Tokuda, T., Ikegawa, M., Komori, M., Kasai, T., Kondo, T., Matsuyama, Y.,
Nirasawa, T., Thiele, H., Tashiro, K., and Nakagawa, M. (2012). Cerebrospinal fluid pro-
teomic patterns discriminate Parkinson’s disease and multiple system atrophy. Movement
Disorders, 27(7):851–857.
Jarrett, J. T., Berger, E. P., and Lansbury Jr., P. T. (1993). The carboxy terminus of the
  amyloid protein is critical for the seeding of amyloid formation: implications for the
pathogenesis of Alzheimer’s disease. Biochemistry, 32(18):4693–4697.
65
Bibliography
Jensen, P. H., Hager, H., Nielsen, M. S., Højrup, P., Gliemann, J., and Jakes, R. (1999). alpha-
synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation
of serine residues 262 and 356. Journal of Biological Chemistry, 274(36):25481–25489.
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., ..., and Stefansson, K.
(2012). A mutation in APP protects against Alzheimer’s disease and age-related cognitive
decline. Nature, 488(7409):96–99.
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., ..., and Stefansson, K.
(2013). Variant of TREM2 Associated with the Risk of Alzheimer’s Disease. New England
Journal of Medicine, 368(2):107–116.
Jucker, M. (2010). The benefits and limitations of animal models for translational research in
neurodegenerative diseases. Nature Medicine, 16(11):1210–1214.
Jucker, M. and Walker, L. C. (2013). Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature, 501(7465):45–51.
Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi,
M., Leimer, U., van Der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H. a., and
Haass, C. (2000). Subcellular localization of wild-type and Parkinson’s disease-associated
mutant alpha -synuclein in human and transgenic mouse brain. The Journal of neuroscience
: the oﬃcial journal of the Society for Neuroscience, 20(17):6365–6373.
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J., Masters, C., Grzeschik, K.-H.,
Multhaup, G., Beyreuther, K., and Müller-Hill, B. (1987). The precursor of Alzheimer’s
disease amyloid A4 protein resembles a cell-surface receptor. Alzheimer Disease Associated
Disorders, 1(3):206–207.
Kelley, B. J., Haidar, W., Boeve, B. F., Baker, M., Shiung, M., Knopman, D. S., Rademakers,
R., Hutton, M., Adamson, J., Kuntz, K. M., Dickson, D. W., Parisi, J. E., Smith, G. E.,
and Petersen, R. C. (2010). Alzheimer disease-like phenotype associated with the c.154delA
mutation in progranulin. Archives of neurology, 67(2):171–7.
Khoonsari, E., Häggmark, A., Lonnberg, M., Mikus, M., Kilander, L., Lannfelt, L., Bergquist,
J., Ingelsson, M., Nilsson, P., Kultima, K., and Shevchenko, G. (2016). Analysis of the
cerebrospinal fluid proteome in Alzheimer’s disease. PLoS ONE, 11(3):1–25.
Kidd, M. (1963). Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature,
197:192–193.
Kleinberger, G., Yamanishi, Y., Suarez-Calvet, M., Czirr, E., Lohmann, E., ..., and Haass, C.
(2014). TREM2 mutations implicated in neurodegeneration impair cell surface transport
and phagocytosis. Science Translational Medicine, 6(243):243ra86–243ra86.
66
Bibliography
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström,
M., Savitcheva, I., Huang, G. F., Estrada, S., Ausén, B., Debnath, M. L., Barletta, J.,
Price, J. C., Sandell, J., Lopresti, B. J., Wall, A., Koivisto, P., Antoni, G., Mathis, C. A.,
and Långström, B. (2004). Imaging Brain Amyloid in Alzheimer’s Disease with Pittsburgh
Compound-B. Annals of Neurology, 55(3):306–319.
Kosik, K. S., Joachim, C. L., and Selkoe, D. J. (1986). Microtubule-associated protein tau (tau)
is a major antigenic component of paired helical filaments in Alzheimer disease. Proceedings
of the National Academy of Sciences, 83(11):4044—-4048.
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen,
J. T., Schols, L., and Riess, O. (1998). Ala30Pro mutation in the gene encoding ↵-synuclein
in Parkinson’s disease. Nature Genetics, 18(2):106–108.
Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiﬀer, R., Jasionowski, M., Haass, C., and
Fahrenholz, F. (1999). Constitutive and regulated alpha-secretase cleavage of Alzheimer’s
amyloid precursor protein by a disintegrin metalloprotease. Proceedings of the National
Academy of Sciences of the United States of America, 96(7):3922–3927.
Lázaro, D. F., Rodrigues, E. F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T., Guerreiro, P.,
Gerhardt, E., Kröhnert, K., Klucken, J., Pereira, M. D., Popova, B., Kruse, N., Mollenhauer,
B., Rizzoli, S. O., Braus, G. H., Danzer, K. M., and Outeiro, T. F. (2014). Systematic Com-
parison of the Eﬀects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation.
PLoS Genetics, 10(11).
Lee, H.-J. J., Khoshaghideh, F., Patel, S., and Lee, S.-J. J. (2004). Clearance of alpha-synuclein
oligomeric intermediates via the lysosomal degradation pathway. J Neurosci, 24(8):1888–
1896.
Lee, J., Retamal, C., Cuitiño, L., Caruano-Yzermans, A., Shin, J. E., Van Kerkhof, P., Mar-
zolo, M. P., and Bu, G. (2008). Adaptor protein sorting nexin 17 regulates amyloid precursor
protein traﬃcking and processing in the early endosomes. Journal of Biological Chemistry,
283(17):11501–11508.
Lee, M. K. and Cleveland, D. W. (1996). Neuronal Intermediate Filaments. Annual Review
of Neuroscience, 19(1):187–217.
Lehnert, S., Jesse, S., Rist, W., Steinacker, P., Soininen, H., Herukka, S. K., Tumani, H.,
Lenter, M., Oeckl, P., Ferger, B., Hengerer, B., and Otto, M. (2012). ITRAQ and multiple
reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients
with Parkinson’s disease dementia. Experimental Neurology, 234(2):499–505.
67
Bibliography
Leinenbach, A., Pannee, J., Dülﬀer, T., Huber, A., Bittner, T., Andreasson, U., Gobom,
J., Zetterberg, H., Kobold, U., Portelius, E., and Blennow, K. (2014). Mass spectrometry-
based candidate reference measurement procedure for quantification of amyloid-beta in Cere-
brospinal fluid. Clinical Chemistry, 60(7):987–994.
Lesage, S. and Brice, A. (2009). Parkinson’s disease: From monogenic forms to genetic sus-
ceptibility factors. Human Molecular Genetics, 18(R1):48–59.
Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J. B.,
Eckert, A., and Müller, W. E. (2007). Mitochondrial Dysfunction: The First Domino in
Brain Aging and Alzheimer’s Disease? Antioxidants Redox Signaling, 9(10):1659–1676.
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D., Oshima, J., Pettingell, W., Yu, C.,
Jondro, P., Schmidt, S., and Wang, K. (1995). Candidate gene for the chromosome 1
familial Alzheimer’s disease locus. Science, 269(5226):973–977.
Li, N., Workman, C. J., Martin, S. M., and Vignali, D. a. a. (2004). Biochemical analysis
of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). Journal of
immunology (Baltimore, Md. : 1950), 173(19):6806–6812.
Licastro, F., Parnetti, L., Morini, M. C., Davis, L. J., Cucinotta, D., Gaiti, A., and Senin,
U. (1995). Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal
fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis.Assoc.Disord.,
9(0893-0341):112–118.
Loane, C. and Politis, M. (2011). Positron emission tomography neuroimaging in Parkinson’s
disease. American Journal of Translational Research, 3(4):323–341.
Mackay, I. R., Rosen, F. S., and Walport, M. J. (2001). Complement. New England Journal
of Medicine, 344(15):1140–1144.
Magdalinou, N., Lees, A. J., and Zetterberg, H. (2014). Cerebrospinal fluid biomarkers in
parkinsonian conditions: an update and future directions. Journal of Neurology, Neuro-
surgery Psychiatry, 85(10):1065–1075.
Magdalinou, N., Noyce, A., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M.,
Blennow, K., Morris, H., Skillbäck, T., Warner, T., Lees, A., Pike, I., Ward, M., Zetter-
berg, H., and Gobom, J. (2017). Identification of candidate cerebrospinal fluid biomarkers
in parkinsonism using quantitative proteomics. Parkinsonism Related Disorders, pages 1–7.
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., and
Jucker, M. (2013). Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic
Mice Overexpressing Amyloid Precursor Protein. Sci. Transl .Med., 5(194):194re2.
68
Bibliography
Maia, L. F., Kaeser, S. A., Reichwald, J., Lambert, M., Obermuller, U., Schelle, J., Odenthal,
J., Martus, P., Staufenbiel, M., and Jucker, M. (2015). Increased CSF Abeta during the very
early phase of cerebral Abeta deposition in mouse models. EMBO Mol Med, 7(7):895–903.
Makarov, A. (2000). Electrostatic axially harmonic orbital trapping: A high-performance
technique of mass analysis. Analytical Chemistry, 72(6):1156–1162.
Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., Van Der Brug,
M., Liu, Y., Ernst, J. A., Watts, R. J., and Atwal, J. K. (2014). Molecular mechanisms of
Alzheimer disease protection by the A673T allele of amyloid precursor protein. Journal of
Biological Chemistry, 289(45):30990–31000.
Mao, P., Meshul, C. K., Thuillier, P., and Reddy, P. H. (2013). Neurotransmitter CART as a
new therapeutic candidate for Parkinson’s disease. Pharmaceuticals, 6(1):108–123.
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah,
G. E., Brahmachari, S., Shin, J.-H., Kang, H. C., Zhang, J., Xu, J., Chen, R., Park, H.,
Andrabi, S. A., Kang, S. U., Gonçalves, R. A., Liang, Y., Zhang, S., Qi, C., Lam, S.,
Keiler, J. A., Tyson, J., Kim, D., Panicker, N., Yun, S. P., Workman, C. J., Vignali, D.
A. A., Dawson, V. L., Ko, H. S., and Dawson, T. M. (2016). Pathological ↵-synuclein
transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.),
353(6307):aah3374–aah3374.
Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., Min, S. W.,
Gan, L., Finkbeiner, S., Huang, E. J., and Farese, R. V. (2012). Progranulin deficiency
promotes neuroinflammation and neuron loss following toxin-induced injury. Journal of
Clinical Investigation, 122(11):3955–3959.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther,
K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceed-
ings of the National Academy of Sciences of the United States of America, 82(12):4245–9.
Mattsson, N., Andreasson, U., Persson, S., ..., Zhang, J., Zetterberg, H., and Blennow, K.
(2011). The Alzheimer’s Association external quality control program for cerebrospinal
fluid biomarkers. Alzheimer’s and Dementia, 7(4):386–395.
Mendez, M. F. (2012). Early-onset Alzheimer’s Disease: Nonamnestic Subtypes and Type 2
AD. Archives of Medical Research, 43(8):677–685.
Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., and Lau, Y. S.
(2002). Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive
mouse model of Parkinson’s disease. Brain Research, 956(1):156–165.
69
Bibliography
Michalski, A., Damoc, E., Lange, O., Denisov, E., Nolting, D., Muller, M., Viner, R., Schwartz,
J., Remes, P., Belford, M., Dunyach, J.-J., Cox, J., Horning, S., Mann, M., and Makarov, A.
(2012). Ultra High Resolution Linear Ion Trap Orbitrap Mass Spectrometer (Orbitrap Elite)
Facilitates Top Down LC MS/MS and Versatile Peptide Fragmentation Modes. Molecular
Cellular Proteomics, 11(3):O111.013698–O111.013698.
Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., MacH, R. H., Klunk,
W. E., Mathis, C. A., Dekosky, S. T., and Morris, J. C. (2006). [11C]PIB in a nondemented
population: Potential antecedent marker of Alzheimer disease. Neurology, 67(3):446–452.
Mishima, T., Fujiwara, T., Sanada, M., Kofuji, T., Kanai-Azuma, M., and Akagawa, K.
(2014). Syntaxin 1B, but not syntaxin 1A, is necessary for the regulation of synaptic vesicle
exocytosis and of the readily releasable pool at central synapses. PLoS ONE, 9(2).
Miyazaki, T., Dierich, A., Benoist, C., and Mathis, D. (1996). Independent modes of natural
killing distinguished in mice lacking Lag3. Science (New York, N.Y.), 272(5260):405–408.
Morgan, T., Wong, A., and Finch, C. (2007). Anti-inflammatory mechanisms of dietary
restriction in slowing aging processes. Interdisciplinary Topics in Gerontology, 35:83–97.
Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D.,
Chang, L., Miller, B., Clark, C., and Green, R. (1995). Reduction of beta-amyloid pep-
tide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Annals of neurology,
38(4):643–648.
Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., Odoy,
S., Fujiwara, H., Hasegawa, M., Iwatsubo, T., Trojanowski, J. Q., Kretzschmar, H. a., and
Haass, C. (2002). Misfolded proteinase Kâresistant hyperphosphorylated. Journal of Clinical
Investigation, 110(10):1429–1439.
Nussbaum, J. M., Seward, M. E., and Bloom, G. S. (2013). Alzheimer disease: a tale of two
prions. Prion, 7(1):14–19.
O’Brien, R. and Wong, P. (2011). Amyloid precursor protein processing and alzheimer’s
disease. Annual review of neuroscience, 1987:185–204.
Olsson, B., Zetterberg, H., Hampel, H., and Blennow, K. (2011). Biomarker-based dissection
of neurodegenerative diseases. Progress in Neurobiology, 95(4):520–534.
Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The role of autophagy-lysosome pathway
in neurodegeneration associated with Parkinson’s disease. Brain, 131(8):1969–1978.
Parkinson, J. (1817). An essay on the shaking palsy. The Journal of neuropsychiatry and
clinical neurosciences, 14(2):223–236.
70
Bibliography
Parkkinen, L., Pirttilâ, T., and Alafuzoﬀ, I. (2008). Applicability of current stag-
ing/categorization of ↵-synuclein pathology and their clinical relevance. Acta Neuropatho-
logica, 115(4):399–407.
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., de Carlo, C., Qureshi, M. M.,
Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A.,
Onofrj, M., Padovani, A., Calabresi, P., and El-Agnaf, O. (2011). Cerebrospinal fluid Tau/↵-
synuclein ratio in Parkinson’s disease and degenerative dementias. Movement Disorders,
26(8):1428–1435.
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Balducci, C., Paciotti,
S., Tambasco, N., Bembi, B., and Bonanni, L. (2014a). Cerebrospinal Fluid Lysosomal
Enzymes and Alpha-Synuclein in Parkinson ’ s Disease. 29(8):1019–1027.
Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., Salvadori,
N., Lisetti, V., Tambasco, N., Rossi, A., Majbour, N. K., El-Agnaf, O., and Calabresi, P.
(2014b). Diﬀerential role of CSF alpha-synuclein species, tau, and A 42 in Parkinson’s
disease. Frontiers in Aging Neuroscience, 6(MAR).
Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tien-
ari, P. J., Pöyhönen, M., and Paetau, A. (2014). A novel alpha-synuclein mutation A53E
associated with atypical multiple system atrophy and Parkinson’s disease-type pathology.
Neurobiology of Aging, 35(9):2180.e1–2180.e5.
Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G.,
Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., and Broersen, K. (2012). Struc-
tural basis for increased toxicity of pathological A 42:A 40 ratios in alzheimer disease.
Journal of Biological Chemistry, 287(8):5650–5660.
Petzold, A. (2005). Neurofilament phosphoforms: Surrogate markers for axonal injury, degen-
eration and loss. Journal of the Neurological Sciences, 233(1-2):183–198.
Phinney, A. L., Horne, P., Yang, J., Janus, C., Bergeron, C., and Westaway, D. (2003). Mouse
models of Alzheimer’s disease: the long and filamentous road. Neurol Res, 25(6):590–600.
Pijnenburg, Y. A. L., Janssen, J. C., Schoonenboom, N. S. M., Petzold, A., Mulder, C., Stig-
brand, T., Norgren, N., Heijst, H., Hack, C. E., Scheltens, P., and Teunissen, C. E. (2007).
CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer’s dis-
ease and controls. Dementia and Geriatric Cognitive Disorders, 23(4):225–230.
Pires, A. O., Teixeira, F., Mendes-Pinheiro, B., Serra, S. C., Sousa, N., and Salgado, A. J.
(2017). Old and New Challenges in Parkinson’s Disease Therapeutics. Progress in Neurobi-
ology.
71
Bibliography
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B.,
Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou,
A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Iorio, G. D.,
Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the ↵ -Synuclein Gene Identified in
Families with Parkinson ’ s Disease. Science, 276(June):2045–2047.
Porcellini, E., Davis, E. J., Chiappelli, M., Ianni, E., Di, G., Forti, P., Ravaglia, G., and Licas-
tro, F. (2008). Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive
decline and Alzheimer’s disease: a potential therapeutic target. Current pharmaceutical
design, 14(26):2659.
Prince, M., Wimo, A., Guerchet, M., Gemma-Claire, A., Wu, Y.-T., and Prina, M. (2015).
World Alzheimer Report 2015: The Global Impact of Dementia - An analysis of prevalence,
incidence, cost and trends. Alzheimer’s Disease International, page 84.
Pringsheim, T., Jette, N., Frolkis, A., and Steeves, T. D. L. (2014). The prevalence of Parkin-
son’s disease: A systematic review and meta-analysis. Movement Disorders, 29(13):1583–
1590.
Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L.,
Houlden, H., and Schapira, A. H. (2013). A novel ↵-synuclein missense mutation in Parkin-
son disease. Neurology, 80(11):1062–1064.
Radde, R., Bolmont, T., Kaeser, S. a., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun,
M. E., Jäggi, F., Wolburg, H., Gengler, S., Haass, C., Ghetti, B., Czech, C., Hölscher, C.,
Mathews, P. M., and Jucker, M. (2006). Abeta42-driven cerebral amyloidosis in transgenic
mice reveals early and robust pathology. EMBO reports, 7(9):940–6.
Rappsilber, J., Ishihama, Y., and Mann, M. (2003). Stop And Go Extraction tips for matrix-
assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in
proteomics. Analytical Chemistry, 75(3):663–670.
Robakis, N., Ramakrishna, N., Wolfe, G., and Wisniewski, H. (1987). Molecular Cloning and
Characterization of a cDNA Encoding the Cerebrovascular and the Neuritic Plaque Amyloid
Peptides. Proceedings of the National Academy of Sciences, 84(12):4190–4194.
Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A.,
Toombs, J., Druyeh, R., Cardoso, M. J., Ourselin, S., Nicholas, J. M., Norgren, N., Mead,
S., Andreasson, U., Blennow, K., Schott, J. M., Fox, N. C., Warren, J. D., and Zetterberg,
H. (2016). Serum neurofilament light chain protein is a measure of disease intensity in
frontotemporal dementia. Neurology, 87(13):1329–1336.
72
Bibliography
Satoh, J.-I., Kino, Y., Yamamoto, Y., Kawana, N., Ishida, T., Saito, Y., and Arima, K. (2014).
PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains. Alzheimer’s research
therapy, 6(9):70.
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S.,
and aria Van der Flier, W. M. (2016). Alzheimer’s disease. Lancet (London, England),
388(10043):505–517.
Schmidt, F. M., Mergl, R., Stach, B., Jahn, I., Gertz, H. J., and Schönknecht, P. (2014).
Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer’s disease.
Neuroscience Letters, 570:81–85.
Schneider, C. a., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years
of image analysis. Nature Methods, 9(7):671–675.
Schultz, K., Wiehager, S., Nilsson, K., Nielsen, J. E., Lindquist, S. G., Hjermind, L. E.,
Andersen, B. B., Wallin, A., Nilsson, C., and Petersén, Å. (2009). Reduced CSF CART in
dementia with Lewy bodies. Neuroscience Letters, 453(2):104–106.
Schupf, N. and Sergievsky, G. H. (2002). Genetic and host factors for dementia in Down’ s
syndrome*. British Journal of Psychiatry, 180(5):405–410.
Selkoe, D. J. (1991). The Molecular Pathology of Alzheimer’s Disease. Neuron, 6:487–498.
Shen, J. and Kelleher, R. J. (2007). The presenilin hypothesis of Alzheimer’s disease: Evi-
dence for a loss-of-function pathogenic mechanism. Proceedings of the National Academy of
Sciences, 104(2):403–409.
Shepherd, C., McCann, H., and Halliday, G. M. (2009). Variations in the neuropathology of
familial Alzheimer’s disease. Acta Neuropathologica, 118(1):37–52.
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., and Ikeda, M. (1995).
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease.
Nature, 375(6534):754–760.
Shulman, J. M., De Jager, P. L., and Feany, M. B. (2011). Parkinson’s Disease: Genetics and
Pathogenesis. The Annual Review of Pathology: Mechanisms of Disease, 6:193–224.
Singh, P. P., Singh, M., and Mastana, S. S. (2006). APOE distribution in world populations
with new data from India and the UK. Annals of Human Biology, 33(3):279–308.
Sisodia, S., Koo, E., Beyreuther, K., Unterbeck, A., and Price, D. (1990). Evidence that
 -Amyloid Protein in Alzheimer’s Disease is not Derived by Normal Processing. Science,
248(4954):492–495.
73
Bibliography
Sisodia, S. S. (1992). Beta-amyloid precursor protein cleavage by a membrane-bound protease.
Proceedings of the National Academy of Sciences, 89(13):6075–6079.
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J. J., De
Deyn, P. P., and Engelborghs, S. (2014). Increased CSF ↵-synuclein levels in Alzheimer’s
disease: Correlation with tau levels. Alzheimer’s and Dementia, 10(5):S290–S298.
Spillantini, G. M., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., and Goedert,
M. (1997). a-Synuclein in Lewy bodies. Nature, pages 839–840.
Strozyk, D., Blennow, K., White, L. R., and Launer, L. J. (2003). CSF AÂ 42 levels correlate
with amyloid-neuropathology in a population-based autopsy study. Neurology, 60(4):652–
656.
Suárez-Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A.,
Alcolea, D., ..., and Haass, C. (2016). sTREM2 cerebrospinal fluid levels are a potential
biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neu-
ronal injury markers. EMBO molecular medicine, 8(5):e201506123.
Subhedar, N. K., Nakhate, K. T., Upadhya, M. A., and Kokare, D. M. (2014). CART in the
brain of vertebrates: Circuits, functions and evolution. Peptides, 54:108–130.
Sveinbjornsdottir, S. (2016). The clinical symptoms of Parkinson’s disease. Journal of Neuro-
chemistry, 139:318–324.
Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S.,
and Ihara, Y. (2009). Beta-Secretase: Successive Tripeptide and Tetrapeptide Release from
the Transmembrane Domain of Beta-Carboxyl Terminal Fragment. Journal of Neuroscience,
29(41):13042–13052.
Tanaka, S., Nakamura, S., Ueda, K., Kameyama, M., Shiojiri, S., Takahashi, Y., Kitaguchi,
N., and Ito, H. (1988). Three types of amyloid protein precursor mRNA in human brain:
their diﬀerential expression in Alzheimer’s disease. Biochemical and biophysical research
communications, 157(2):472–9.
Tansey, M. G. and Goldberg, M. S. (2010). Neuroinflammation in Parkinson’s disease: Its role
in neuronal death and implications for therapeutic intervention. Neurobiology of Disease,
37(3):510–518.
Tapiola, T., Alafuzoﬀ, I., Herukka, S., and et Al (2009). Cerebrospinal fluid  -amyloid 42 and
tau proteins as biomarkers of alzheimer-type pathologic changes in the brain. Archives of
Neurology, 66(3):382–389.
74
Bibliography
Terry, R. D. (1963). The fine structure of neurofibrillary tangles in Alzheimer’s disease. Journal
of Neuropathology Experimental Neurology, 22(4):629—-642.
Thal, D. R., Rub, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition in the
human brain and its relevance for the development of AD. Neurology, 58(12):1791–1800.
Thinakaran, G. and Koo, E. H. (2008). Amyloid precursor protein traﬃcking, processing, and
function.
Thomas, B. and Flint Beal, M. (2007). Parkinson’s disease. Human Molecular Genetics,
16(R2):R183–94.
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., Ishigami,
N., Tamaoka, A., Nakagawa, M., and El-Agnaf, O. M. (2010). Detection of elevated levels of
↵-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75(20):1766–
1772.
Tosato, M., Zamboni, V., Ferrini, A., and Cesari, M. (2007). The aging process and potential
interventions to extend life expectancy. Clinical interventions in aging, 2(3):401–412.
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., and Cox,
J. (2016). The Perseus computational platform for comprehensive analysis of (prote)omics
data. Nature methods, 13(9):731–40.
UNFPA (2012). Ageing in the Twenty-First Century: A Celebration and A Challenge. Tech-
nical report.
Upadhya, M. A., Shelkar, G. P., Subhedar, N. K., and Kokare, D. M. (2016). CART modulates
the eﬀects of levodopa in rat model of Parkinson’s disease. Behavioural Brain Research,
301:262–272.
Van Broeckhoven, C., Haan, J., Bakker, E., Hardy, J. A., Van Hul, W., Wehnert, A.,
Vegter-Van der Vlis, M., and Roos, R. A. (1990). Amyloid beta protein precursor gene
and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science (New York, N.Y.),
248(4959):1120–2.
van der Putten, H., Wiederhold, K. H., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauﬀ-
mann, S., Hofele, K., Spooren, W. P., Ruegg, M. A., Lin, S., Caroni, P., Sommer, B., Tolnay,
M., and Bilbe, G. (2000). Neuropathology in mice expressing human alpha-synuclein. The
Journal of neuroscience : the oﬃcial journal of the Society for Neuroscience, 20(16):6021–9.
Van Kampen, J. M., Baranowski, D., and Kay, D. G. (2014). Progranulin gene delivery protects
dopaminergic neurons in a mouse model of Parkinson’s disease. PLoS ONE, 9(5):e97032.
75
Bibliography
Vassar, R. (1999). Beta-Secretase Cleavage of Alzheimer’s Amyloid Precursor Protein by the
Transmembrane Aspartic Protease BACE. Science, 286(5440):735–741.
Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., and Schenk, D. B. (1993). Characterization
of beta-amyloid peptide from human cerebrospinal fluid. Journal of neurochemistry, 61:1965–
1968.
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., and Rowe, C. C. (2015). Tau
imaging: Early progress and future directions. The Lancet Neurology, 14(1):114–124.
Vos, T., ..., and Zuhlke, L. J. (2016). Global, regional, and national incidence, prevalence, and
years lived with disability for 310 diseases and injuries, 1990â2015: a systematic analysis for
the Global Burden of Disease Study 2015. The Lancet, 388(10053):1545–1602.
Walker, L. C. and Jucker, M. (2015). Neurodegenerative Diseases: Expanding the Prion
Concept. Annual Review of Neuroscience, 38(1):87–103.
Wang, Y.-c., Liu, H.-c., Liu, T.-y., and Hong, C.-j. (2001). Genetic Association Analysis of
Polymorphism in Parkinson ’ s Disease. (201):254–256.
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., and Rubinsztein, D. C. (2003). ↵-
synuclein Is Degraded by Both Autophagy and the Proteasome. Journal of Biological Chem-
istry, 278(27):25009–25013.
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., and
Nielsen, H. M. (2013). Low CSF Levels of Both ↵-Synuclein and the ↵-Synuclein Cleaving
Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 8(1).
Whalley, L. J., Deary, I. J., Appleton, C. L., and Starr, J. M. (2004). Cognitive reserve and
the neurobiology of cognitive aging. Ageing Research Reviews, 3(4):369–382.
Wirths, O., Weis, J., Szczygielski, J., Multhaup, G., and Bayer, T. A. (2006). Axonopathy
in an APP/PS1 transgenic mouse model of Alzheimer’s disease. Acta Neuropathologica,
111(4):312–319.
Wiśniewski, H. M., Narang, H. K., and Terry, R. D. (1976). Neurofibrillary tangles of paired
helical filaments. Journal of the neurological sciences, 27(2):173–81.
Yamamoto, M., Kondo, I., Ogawa, N., Asanuma, M., Yamashita, Y., and Mizuno, Y.
(1997). Genetic association between susceptibility to Parkinson’s disease and alpha1-
antichymotrypsin polymorphism. Brain research, 759:153–155.
Yan, Y. and Wang, C. (2006). Abeta42 is more rigid than Abeta40 at the C terminus: impli-
cations for Abeta aggregation and toxicity. Journal of molecular biology, 364(5):853–62.
76
Bibliography
Yuan, A., Rao, M. V., Veeranna, and Nixon, R. A. (2012). Neurofilaments at a glance. Journal
of Cell Science, 125(14):3257–3263.
Yuan, a., Sershen, H., Veeranna, Basavarajappa, B. S., Kumar, a., Hashim, a., Berg, M.,
Lee, J.-H., Sato, Y., Rao, M. V., Mohan, P. S., Dyakin, V., Julien, J.-P., Lee, V. M.-Y.,
and Nixon, R. a. (2015). Neurofilament subunits are integral components of synapses and
modulate neurotransmission and behavior in vivo. Molecular psychiatry, 20(8):986–94.
Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal,
L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., Del Ser, T.,
Muñoz, D. G., and De Yebenes, J. G. (2004). The New Mutation, E46K, of alpha-Synuclein
Causes Parkinson and Lewy Body Dementia. Annals of Neurology, 55(2):164–173.
Zetterberg, H., Skillback, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M.,
Weiner, M. W., and Blennow, K. (2015). Association of Cerebrospinal Fluid Neurofilament
Light Concentration With Alzheimer Disease Progression. JAMA Neurol, 73(1):1–8.
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., Chung, K. A.,
Millard, S. P., Nutt, J. G., and Montine, T. J. (2008). CSF multianalyte profile distinguishes
Alzheimer and Parkinson diseases. American Journal of Clinical Pathology, 129(4):526–529.
77
Curriculum Vitae
Name: Timo Eninger
Address: Beim Herbstenhof 38
72076 Tübingen - Germany
Phone: +49 176 57765028
E-Mail: Timo.Eninger@gmx.de
Date of Birth: 30.06.1988
Place of Birth: Saulgau, jetzt: Bad Saulgau
Citizenship: German
Education and Academic Degrees
06/2014 - present: PhD in Cellular &Molecular Neuroscience
PhD student in Neuroscience, Department of Cellular Neurology, Hertie Institute for
Clinical Brain Research, German Center for Neurodegenerative Diseases and Graduate
Training Centre of Neuroscience, Tübingen
Advisor: Prof. Mathias Jucker. Title: “CSF protein dynamics in murine models of
a-synucleinopathy and cerebral b-amyloidosis”
01/2014 - 05/2014: Research Assistant
Student assistant in the Proteome Center Tübingen, Eberhard Karls University, Tübin-
gen. Advisor: Prof. Boris Maček.
10/2011 - 11/2013: Master of Science in Biology
Eberhard Karls University, Tübingen. Major in Neurobiology
78
Curriculum Vitae
Advisor: Prof. Boris Maček. Master Thesis: ”Quantitative phosphoproteomics of STEK
cell lines provides new insights into signal transduction mechanisms implicated in fragile
X syndrome”
10/2008 - 09/2011: Bachelor of Science in Biology
Eberhard Karls University, Tübingen.
Advisor: Dr. Annette Denzinger. Bachelor Thesis: “Audiovokale Reaktionszeiten bei
Fledermäusen”
Publications and Abstracts
Eninger, T., Müller, S. A., Bacioglu, M., Schweighauser, M., Lambert, M., Maia, L.,
Kahle, P. J., Lichtenthaler, S., Jucker, M., Kaeser, S. A. - CSF proteome profiling in
murine models of a-synucleinopathy and cerebral b-amyloidosis reveals novel biomarker
candidates.
(manuscript in preparation)
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser,
M., Eninger, T., Lambert, M., Pilotto, A., Shimshek, D. R., Neumann, U., Kahle, P.
J., Staufenbiel, M., Neumann, M., Maetzler, W., Kuhle, J., Jucker, M. (2016). Neurofil-
ament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models
and in Neurodegenerative Diseases. Neuron, 91(1), 56–66.
Matic*, K., Eninger*, T., Bardoni, B., Davidovic, L., & Macek, B. (2014). Quanti-
tative phosphoproteomics of murine Fmr1 -KO cell lines provides new insights into
FMRP-dependent signal transduction mechanisms. Journal of Proteome Research,
13(10), 4388–4397.
*contributed equally to this work
Abstract: Eninger, T., Müller, S. A., Bacioglu, M., Schweighauser, M., Häsler, L.,
Kahle, P., Jucker, M., Lichtenthaler, S., Kaeser, S. A. (2016) “Proteome Changes in the
Cerebrospinal Fluid of Mouse Models for b-Amyloidosis and a-Synucleinopathy”. Soci-
ety for Neuroscience - Annual Meeting, San Diego, USA
79
List of Figures
1 The structure of a-synuclein and mutations linked to familial Parkinson’s
disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Historic illustrations of plaques from the brain of Auguste Deter . . . . 5
3 Sequential cleavage of APP occurs by two pathways . . . . . . . . . . . 8
4 Mutations in APP associated with familial Alzheimer’s disease . . . . . 10
5 Mouse models of neurodegenerative diseases used for CSF proteome anal-
ysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
6 Schematic design of a Q-Exactive mass spectrometer . . . . . . . . . . 16
7 CSF preparation in mice . . . . . . . . . . . . . . . . . . . . . . . . . . 19
8 Workflow and methods utilized for the analysis of individual A30P-aSyn,
APPPS1 and WT CSF proteomes . . . . . . . . . . . . . . . . . . . . . 20
9 CSF proteome changes in A30P-aSyn compared to age-matched controls
at 18, 11 and 3 months of age . . . . . . . . . . . . . . . . . . . . . . . 29
10 Selected proteins in CSF of A30P-aSyn . . . . . . . . . . . . . . . . . . 31
12 CSF proteome changes in APPPS1 compared to age-matched controls at
18 and 3 months of age . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
13 Selected proteins in CSF of APPPS1 . . . . . . . . . . . . . . . . . . . 34
15 Specificity of CSF proteome alterations . . . . . . . . . . . . . . . . . . 36
16 Proteins of the complement system enriched in A30P-aSyn CSF . . . . 36
17 Levels of (soluble) LAG3 in CSF, determined by western blot . . . . . . 38
18 Increase of NfL in CSF and plasma of a-Syn and APP transgenic mice 40
11 Pathways altered in the CSF of A30P-aSyn . . . . . . . . . . . . . . . . 44
14 Pathways altered in the CSF of APPPS1 at 18 months of age . . . . . 46
80
List of Tables
1 CSF proteomes by numbers . . . . . . . . . . . . . . . . . . . . . . . . 26
2 Representation of UniProt terms subcellular location . . . . . . . . . . 27
3 Top 25 increased proteins in CSF of A30P-aSyn mice . . . . . . . . . . 41
4 Significantly decreased proteins in CSF of A30P-aSyn . . . . . . . . . . 42
5 Enrichment analysis of 220 significantly altered proteins in CSF from 18
month old A30P-aSyn . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
6 Top 25 altered proteins in CSF of APPPS1 mice . . . . . . . . . . . . . 45
81
